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1 General Introduction
1.1 The immune system
Immunity (derived from immunitas: Latin for exemption from civic duties and pro-
secution) means protection from disease and especially infectious disease. Cells and
molecules involved in such protection constitute the immune system and the response to
the introduction of a foreign agent is known as the immune response. Not all immune
responses protect from disease; some foreign agents, such as the allergens found in house
dust mite, cat dander or rye grass pollen, cause disease as a consequence of inducing
an immune response. Constantly dealing with natural enemies in form of viruses, bac-
teria, fungi and other parasites, the immune system is facilitated with a great variety
of different mechanism of defense. These, unfortunately, come along with the risk for
various malfunctions, e.g. allergy, or tumor development (Figure 1.1). Likewise some
individuals mount immune responses to their own tissues as if they were foreign agents.
Thus, the immune response can cause the autoimmune diseases common to man such
as multiple sclerosis, diabetes, rheumatoid arthritis or myasthenia gravis. Most indi-
viduals do not suffer from autoimmune diseases because they have developed tolerance
towards their own (self) tissues. We are constantly being exposed to infectious agents
and yet, in most cases, we are able to resist these infections. It is our immune system
that enables us to resist infections. The immune system is composed of two major sub-
divisions, the innate immune system and the adaptive immune system. The function of
the innate immunity is based on the recognition of pathogen-associated molecular pat-
terns (PAMPs) by preformed receptors and effector cells. The components of an innate
immune response are inflammatory cells such as macrophages and neutrophils, natural
killer cells (NK cells), γδ T cells, B-1B cells and the complement system. In addition,
the innate immune system also has anatomical features that function as barriers to in-
fection. Although immune system consits of tow arms which have distinct functions,
there is interplay between these systems (i.e., components of the innate immune system
influence the adaptive immune system and vice versa).
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Figure 1.1: A model of innate and adaptive immune-cell function during
inflammation-associated cancer development.
Antigens that are present in early neoplastic tissues are transported to lymphoid or-
gans by dendritic cells (DCs) that activate adaptive immune responses resulting in both
tumor-promoting and antitumor effects. The pathways that regulate DC trafficking
during early cancer development and the exact nature of the antigen(s) remains to be
established. Activation of B cells and humoral immune responses results in chronic ac-
tivation of innate immune cells in neoplastic tissues. Activated innate immune cells,
such as mast cells, granulocytes and macrophages, promote tumor development by the
release of potent pro-survival soluble molecules that modulate gene expression programs
in initiated neoplastic cells, culminating in altered cell-cycle progression and increased
survival. Inflammatory cells positively influence tissue remodelling and development of
the angiogenic vasculature by production of pro-angiogenic mediators and extracellular
proteases. Tissues in which these pathways are chronically engaged exhibit an increased
risk of tumor development. By contrast, activation of adaptive immunity also elicits anti-
tumor responses through T cell-mediated toxicity (by induction of FAS, perforin and/or
cytokine pathways) in addition to antibody-dependent cell-mediated cytotoxicity and
antibody-induced complement-mediated lysis.
During evolution, the innate immune system evolved much earlier than the adaptive
immune system. However, as the receptors involved in innate immune sytem are of
restricted diversity, it is not as flexible as the adaptive immune system. Additionaly, it
can not generate an immunological memory. Adaptive immunity also known as acquired
2
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immune response is based on clonal selection of antigen-specific effector lymphocytes and
on the generation of memory cells to prevent reinfection [1, 2]. The adaptive immune
system requires some time to react to an invading organism, whereas the innate immune
system includes defenses that, for the most part, are constitutively present and ready
to be mobilized upon infection. Using receptors whose specificities do not have to be
genetically encoded, the adaptive immune sytsem is able to respond to high numbers
of foreign antigens. The adaptive immune response is characterized by the humoral
immunity (latin: humor - moisture, fluid) and the cellular immunity. Humoral immu-
nity can protect against extracellular antigens and toxins supplying antibodies which are
secreted by B lymphocytes activated by antigen-specific T helper cells (TH2). Intracellu-
lar pathogens (viruses, intracellular bacteria) were defended by the cellular immunity as
well as tumors. Cellular immunity is mainly based on cytotoxic T lymphocytes (CTLs)
and inflammatory TH1 cells. For activation of CTLs interactions between professional
antigen-presenting cells (APCs), most notably dendritic cells (DCs) and TH1 cells are
necessary. After interaction by pathogenic structures with PAMP-receptors on the sur-
face, DCs become activated and are able to take up antigen in the periphery, travel to
peripheral immune organs and present antigen on MHC molecules to T cells. Therefore,
one may say that DCs take place between innate and adaptive immunity.
1.2 Major histocompatibility complex
1.2.1 MHC molecules
The Major Histocompatibility complex (MHC) contains at least 128 functional genes,
more than 20% of which have functions in immunity, and is the most gene-dense re-
gion of the human genome. The Major Histocompatibility Complex (MHC) is a set
of molecules displayed on cell surfaces that are responsible for lymphocyte recognition
and antigen presentation. In humans it is called human leukocyte antigens (HLA). The
MHC molecules control the immune response through recognition of "self" and "non-
self" and, consequently, serve as targets in transplantation rejection. The class I and
class II MHC molecules belong to a group of molecules known as the Immunoglobulin
Supergene Family, which includes immunoglobulins, T cell receptors, CD4, CD8, and
others. The Major Histocompatibility Complex is encoded by a large, highly polymor-
phic gene cluster, located on human chromosome 6 (Figure 1.2).
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This region is usually divided into class I, II and III antigenic region.
Figure 1.2: Gene map of the human leukocyte antigen (HLA) region.
The HLA region spans 4 x 106 nucleotides on chromosome 6p21.1 to p21.3, with class
II, class III and class I genes located from the centromeric (Cen) to the telomeric (Tel)
end. HLA class I molecules restrict CD8+ cytotoxic T lymphocyte function and mediate
immune responses against ’endogenous’ antigens and virally infected targets, whereas
HLA class II molecules are involved in the presentation of ’exogenous’ antigens to T
helper cells. The HLA class III region contains many genes encoding proteins that are
unrelated to cell-mediated immunity but that nevertheless modulate or regulate immune
responses in some way, including tumor necrosis factor (TNF), heat shock proteins (Hsps)
and complement proteins (C2, C4)
There are two major classes of MHC molecules, both of which consist of an α and
a β chain, but from different sources. MHC class I molecules (MHC I) consist of
one membrane-spanning α chain (heavy chain) produced by MHC genes which is non-
covalently linked to one β chain (light chain or β2-microglobulin (β2m)) produced by
the β2-microglobulin gene. In humans there are three different heavy chains: HLA-A,
HLA-B and -C. The α chain has a short cytoplasmic C-terminal part, a transmembrane
domain and three extracellular domains (α1-α3). The two N-terminal domains α1-α2
form a peptide binding groove which is closed at both ends and accommodates the pre-
sented peptide with a length of 8-10 amino acids. Whereas MHC class II molecules
(MHC II) consist of two membrane-spanning chains, α and β, of similar size and both
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produced by MHC genes. Class II molecules in humans are divided into HLA-DR,-DQ
and DP. In contrast to MHC class I molecules, the peptide binding groove is open at both
ends what allows binding of longer peptides with 10-15 amino acids. Many proteins are
present in more than one genetic variant in human populations: the differences between
such proteins are known as polymorphisms, and most polymorphic proteins are found
in two or three variant forms. The classical HLA class I molecules are present in almost
2000 different variants (Table 1.1). Polymorphism on this scale is unknown in any other
protein and is believed to reflect selection for resistance to disease under pressure from
highly mutable pathogens. There are a large number of genetic variants (alleles) at each
genetic locus. Crucially many of these alleles are represented at significant frequency (>
1%) in the population, and in addition the alleles generally differ from one another by
many (up to 30) amino acid substitutions. Thus the evolution of diversity in peptide
binding is driven by the diversity and mutability of the infectious agents that threaten
the survival of animals.
Table 1.1: Number of known HLA alleles as of January 2008 (data from the Anthony
Nolan Trust, HLA informatics group (http://www.anthonynolan.com/HIG)
Gene locus Number of alleles
HLA-A 630
HLA-B 979
HLA-C 338
1.3 Antigen processing
1.3.1 Mechanisms of MHC class I restricted antigen processing
MHC class I molecules present peptides from cytosolic proteins [3]. The peptides are
generated by exo- and endoproeolytic events during the physiologocal protein turnover
which leads to different lenght variants. A large multienzyme complex called ubiquitin-
proteasome generates C-termini of T cell epitopes. Proteasomes are multicatalytic and
multi-subunit enzyme complexes which represent approx. 1% of the total cell protein
and occur as the major proteolytic component in the nucleus and cytosol of all eu-
karyotic cells. The essential function of proteasomes is the proteolysis of misfolded or
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nonfunctional proteins or of usually regulatory proteins designed for rapid degradation.
Another function of proteasomal degradation of a multiplicity of cellular or viral proteins
is the generation of peptide ligands for major histocompatibility (MHC) class I molecules
which are required for T cell-mediated immune response. Proteasome targets are usu-
ally marked for proteasomal degradation by attachment of oligomeric forms of ubiquitin
(Ub). Ub is a highly conserved protein of 76 amino acids in length, which is covalently
coupled to target proteins. The conjugation of Ub molecules results in the formation
of "poly-Ub chains". In general, multimers of four Ub molecules are required in order
to function as a signal for degradation by the proteasome. Ubiquitination itself is re-
versible, and Ub molecules can be removed again from the target molecule by a multitude
of Ub hydrolases. The 26S proteasome is a 2.5 megadalton (MDa) multienzyme complex
which consists of approximately 31 subunits [4]. The proteolytic activity of the protea-
some complex is provided by a core structure, the 20S proteasome. The 20S proteasome
forms a complicated multienzyme complex consisting of 14 nonidentical proteins, which
is arranged in two alpha and two beta rings in an .alpha.beta.beta.alpha. order [4]. The
substrate specificity of the 20S proteasome comprises three essential proteolytic activi-
ties: a chymotrypsin-like (cleavage after hydrophobic residues), a trypsin-like (cleavage
after basic residues) and a caspase-like (cleavage after acidic residues) [5] which are lo-
cated in the beta subunits δ/Y, Z , and X. The enzymic activities of the 20S proteasome
are controlled by attachment of the 19S regulatory subunits which together form the
active 26S proteasome particle. The 19S regulatory subunits are involved in the recog-
nition of polyubiquitinated proteins and in the unfolding of target proteins. The 26S
proteasome activity is ATP-dependent and degrades almost exclusively only polyubiqui-
tinated proteins. The catalytically active beta subunits of the 20S proteasome (δ/Y, Z
,X) may be replaced by γ-interferon-inducible MHC-encoded low molecular weight pro-
tein 2 (LMP2), MECL-1 and low molecular weight protein 7 (LMP7) which then form
the "immuno proteasome" [6]. The immuno active-active form of the proteasome is able
to enhance the generaton of peptides presented on MHC I. The peptides generated are
transported into the ER using the transporter associated with antigen processing (TAP)
[7]. In the ER MHC I heavy chain-β2m heterodimers are loaded with peptides through
interactions in the peptide-loading complex which consists additionally of the trans-
membrane glycoprotein tapasin, the chaperone calreticulin and the thiol oxidoreductase
ERp57 [8].
6
General Introduction
The accumulated MHC I heavy chain, β2m and peptide complexes are then transported
to the cell surface where they interact with CD8+ T cells (Figure 1.3).
Figure 1.3:MHC class I antigen processing and antigen presentation pathways.
In general, MHC class I presented peptides are derived from intracellular proteins (a).
These are degraded by the proteasome and transported through the transporter asso-
ciated with antigen processing (TAP) in to the endoplasmic reticulum. There, newly
synthesized MHC class I molecules are stabilized by calnexin until β2 microglobulin
binds to the complex. The partial folded MHC class I complex binds to the TAP com-
plex, and, after binding of peptide, the peptide/MHC complex is transported through
the Golgi apparatus to the cell surface. Alternatively, exogenous proteins are phagocy-
tosed, and endocytosed antigens may exit the endosomal pathway into the cytosol, either
before or after processing, where they can enter the classical MHC class I presentation
pathway (b). These proteins are retro-transported out of the endoplasmic reticulum and
degraded by the proteasome. The degraded peptides can now enter the normal pathway
through the TAP complex.
1.3.2 Mechanisms of MHC class II restricted antigen processing
MHC class II molecules present peptides from exogenous proteins acquired by endocy-
tosis or from internalized plasma membrane proteins to CD4+ T cells. Once an anti-
gen is internalized, it is degraded into peptides within compartments of the endocytic
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processing pathway. The endocytic pathway appears to involve increasingly acidic com-
partments: early endosomes (pH 6-6.5); late endolysosomes (pH 4.5-5). Internalized
antigen moves from early to late endosomes, encountering hydrolytic enzymes and a
lower pH. Lysosomes contain a unique collection of more than 40 acid dependent hydro-
lases: Within the compartments of the endocytic pathway, the antigen is degraded into
oligopeptids of about 13-18 amino acid residues, which bind to class II MHC molecules
[9]. MHC class II α- and β-chains are synthesized into the ER and transported in
association with the trimeric invariant chain (li) to the MHC class II loading compart-
ment. The invariant chain contains sorting signals in its cytoplasmic tail that directs the
transport of the class II MHC complex from the trans-Golgi network to the endocytic
compartments [10]. The class II MHC invariant chain complexes are transported from
ER through Golgi complex and trans-Golgi network to the endosomes. As the proteolytic
activity increases in endosomes the invariant chain is gradually degraded. However, a
short fragment of the invariant chain termed CLIP (class II associated invariant chain
peptide) remains bound to the class II molecule. CLIP physically occupies the peptide
binding groove of the class II MHC molecule, but within the loading compartment it is
replaced by the later presented peptide. Two nonclassical class II MHC molecules, called
HLA-DM and HLA-DO play a role in the removal of CLIP and in the subsequent loading
of class II molecules with antigenic peptides [11]. Summarizing, in a classical view, MHC
class I molecules present peptides from intracellular source proteins, whereas MHC class
II molecules present antigenic peptides from exogenous and membrane proteins (Figure
1.3). However, alternative pathways for delivering peptides have been described. It is
known that MHC class I molecules are able to present peptides derived from exogenous
antigens by a process called cross presentation [12]. Intracellular proteins, in contrast,
can be presented by MHC class II molecules [13]. It was shown that autophagy plays
a role in the MHC class II restricted presentation of peptides from intracellular pro-
teins [14]. Autophagy is the degradation of intracellular components in lysosomes and
is therefore relevant in the endosomal/lysosomal degradation pathway.
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1.4 T lymphocytes
Compared to the MHC complex, T cells are also very diverse in their phenotype, their
function and in the target structures they recognize. Both CD4+ and CD8+ T cells can
only recognize antigen when it is presented with a self MHC molecule on the membrane
of an antigen presenting cell. This attribute is called self-MHC restriction. The self MHC
restriction of CD8+ T cells was first demonstrated by R. Zinkernagel and P. Doherty in
1974 [15]. In their experiments, mice were immunized with lymphocytic choriomeningitis
(LCM) virus; several days later, the animals´ spleen cells, which included T cells killed
only syngeneic virus infected target cells. Early in development, T lymphocytes are
able to differentiate in T cells expressing αβ-T cell receptors (αβ-TCR) or γδ-T cell
receptors. γδ-T cells are supposed to recognize heat-shock proteins and non-peptidic
antigens such as sphingolipids bound to nonclassical MHC molecules such as CD1 and,
additionally, might have regulatory effects. αβ T cells (NK T cells, CD8+ T cells or
CD4+ T cells) recognize processed antigen presented MHC molecules on the surface of
cells. The decision whether to become a CD8+ T cell or a CD4+ T cell is made during
the positive selection within the thymus. Double positive (CD4+ CD8+) T cells pass
through the thymus during development where they undergo a positive selection by self
MHC molecules. Binding to a MHC class I molecule results in loss of CD4 expression,
therefore the T cell becomes CD8 positive. If the T cell binds to MHC class II molecules
it becomes CD4 positive. T cells with TCR which neither binds to MHC class I nor
MHC class II undergo apoptosis. Negative selection removes T cells expressing a TCR
which recognizes self-peptides to prevent self-destruction. Anyhow, several antigens
presented in tissues or organs are not present in the thymus. Such self-reactive T cells
recognizing peptides from those antigens become anergic in the periphery, because these
T cells lack additional signals needed during the first antigen contact. All T cells passed
positive and negative selection in the thymus can distinguish between self and non-self
or malignant antigens and are named naive T cells which circle through the body via
the blood and lymph streams. Contact between a professional APC, such as dendritic
cells, B cells or macrophages, via MHC/peptide complex and a costimulatory second
signal leads to the activation of the T cell, a process called priming. After this priming
process activated T cells proliferate and differentiate into armed effector T cells, either
cytotoxic T lymphocytes (CTLs), in the case of CD8+ T cells, or TH1 and TH2 cells, in
the case of CD4+ T cells. CTLs are able to destroy their target cells via the induction
9
General Introduction
of apoptosis, either using perforin and granzymes [16] or Fas-ligand interaction [18; 19]
(Figure 1.4). TH1 cells secrete IFNγ and interleukin 2 (IL-2) [17] leading to activation
of macrophages and CD8+ T cells. TH2 cells support a humoral immune response by
secretion of IL-4 [18] what leads to an activation of antibody secreting B cells and the
complement system. Another T cell population was described which are CD4+ and
express constitutively CD25 [19]. These cells were named regulatory T cells (Treg).
They are able to inhibit T cell reactions, a process which is not completely understood
until now.
Figure 1.4: CTL-mediated cytotoxicity.
(a) Indirect killing of target cells by release of tumor necrosis factor-alpha and IFN-
gamma. (b) Induction of apoptosis in target cells via death receptor triggering. (c)
Direct killing by release of granzyme B and perforin into the intercellular space between
CTL and target cell. TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor;
IFNR, IFN receptor; Fas-L, Fas ligand.
1.5 Immunotherapy in cancer
1.5.1 Tumor associated antigens
The existence of structures distinguishing tumors from normal self is the indispensable
basis for cancer immunotherapy. Nearly all possibilities for tumor associated antigens
one can think about have been found. This is not surprisingly if one concerns, that every
10
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alteration occuring during tumorigenesis at the protein level can potentially cause recog-
nition by T cells, provided that the altered protein can be processed and presented by
MHC molecules. Table 1.2 shows a classification of tumor rejection antigens (*adapted
from Rammensee et al.) [20]. Knowledge about which of such tumor-associated antigens
(TAAs) are expressed by the specific tumor, how they may arise, and what the advan-
tages and restrictions are for different types of TAAs, is an important condition for the
design of suitable therapeutic approaches. Despite the identification of a considerable
number of TAAs, the number of identified TAAs is still far away from beeing sufficient
for substantial immunotherapeutical approaches. One reason therefore is, that the so
far known TAAs are restricted to very few cancer species and HLA alleles and this leads
to the question how many percent of all patients fit to the vaccine.
Table 1.2: classes from tumor antigens*
11
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1.5.2 Clinical trials
Most cancer patients are treated with some combination of surgery, radiation, and
chemotherapy. Radiation and chemotherapy have the disadvantage of destroying healthy
as well as malignant cells. Patients often suffer from severe toxicity and lack of speci-
ficity of the therapy towards tumor cells. New therapeutic concepts are being developed
in addition to the standard therapy. The number of different types of vaccines used in
clinical trials until now is immense. Several studies verified that the immune system
can be manipulated to specifically recognize and eliminate tumor cells [21, 22]. During
the last years, many different approaches have been used to activate the immune system
towards the tumor. One of the most promising strategies deals with the immunization
with peptides of proteins produced by the tumor in combination with adjuvants such
as GM-CSF or keyhole-limpet hemocyanin (KLH) [23], Interleukin 2 [24], Montanide
ISA-51 [25], tumor associated [26] or artificial MHC class II ligands [27]. Dendritic cells
(DCs) also play an important role in activating the immune sytem, e.g. transfection
of dendritic cells with total RNA [28] or RNA coding for defined tumor antigens [29],
or DCs loaded with proteins [30, 31] or MHC class I peptides from tumor associated
antigens [32]. Moreover, there are approaches using hybrid cells designed by fusion of
tumor cells and professional antigen presenting cells [33, 34] irradiated allogenic [35]
or autologous tumor cells [36] which are manipulated to become more immunogenetic.
Recombinant viruses used as transporters for DNA coding for tumor rejection [37] or
autologous tumor-derived heat shock proteins [38]. All vaccines made from autologous
tumors have the advantage that the number of antigens is as high as the molecular
changes within this tumor. Other advantages are that the vaccine can be applied inde-
pendent of the HLA-type and may include T helper cell epitopes. But these advantages
are faced by some serious drawbacks: in some cases, the amount of the vaccine is related
to the tumor size, and therefore, limited with respect to the number of possible repeated
vaccinations; an innovative strategy for vaccination should combine as well induction of
therapeutic T cell immunity in form of tumor-specific effector T cells as protective T
cell immunity in form of tumor-specific memory T cells which can control tumor relapse
[39–41].
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1.5.3 Adoptive transfer of Lymphocytes
Despite the attractiveness of active in vivo induction of anti-tumor T cell reactions,
adoptive T cell transfer has so far been the more succesfull approach [42]. While allo-
genic T cell transfer has the advantage of mediating an associated graft-versus-tumor
(GvT) effect by reactions against tumor minor histocompatibility antigens [43], this is
accompanied by the risk of severe graft-versus-host disease (GvHD) in the patient [44].
Therefore, autologous approaches are often employed, such as the isolation of tumor-
infiltrating lymphocytes (TILs) followed by an in vitro expansion of tumor-reactive TILs
and reinfusion into the patient [45, 46]. Several studies have been shown that cytotoxic
T cells are able to recognize tumor rejection antigens on tumor cells and therefore may
contribute to tumor regression [47, 48]. Sources of such T cells varies from cells gen-
erated by several rounds of ex vivo stimulation to cells isolated from autologous tumor
tissue [45, 49, 50]. Adoptive transfer not only plays a role in tumor regression but also in
the protection of viral diseases such as HCMV or EBV. Adoptively transferred HCMV-
specific CTL clones [51, 52] or T cell lines [53] have successfully protected patients at risk
from HCMV disease. CD4+ helper T cells also play an important role in orchestrating
the effector function of anti-tumor T cell responses [54]. Therefore the identification of
CD4+ T cell epitopes derived from tumor-associated antigens has recently been a major
focus of attention [55, 56]. Alltogether, due to their specificity directly coupled to potent
effector functions, T cells are an attractive means for tumor immunotherapy.
1.6 Altered peptide ligands
Peptide vaccinations have some limitations due to the restriction of peptides to their
specific HLA-type, the limited number of known TAA peptides, or the possibly short
half-life of MHC:peptide complexes on DCs after loading, which may cause dissociation
of a large proportion of MHC:peptide complexes already on the way to draining lymph
nodes. The latter point has been addressed by various attempts to modify natural MHC
ligands in order to increase their affinity to MHC proteins [57, 58]. The modified peptides
are then so called altered peptide ligands(APLs); this can be achievd either through the
modification of amino acid residues involved in MHC binding, or those that are predicted
to contact the TCR [59, 60]. For instance, the immunogenicity of the human melanoma
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peptides, Melan-A/MART-1 and gp100, and that of a prostate-specific antigen peptide
has been improved by amino acid substitutions at anchor positions that increase peptide
MHC class I binding affinity [57, 61, 62]. These peptides showed enhanced binding to
the HLA-A2 molecule and enhanced stability of the peptide-MHC complex that results
in improved in vitro T cell activation.
1.7 Analysis of antigen-specific T cell responses
1.7.1 Characterization of T cells recognizing tumor antigens
The usually low frequency of T cells specific for an antigen is a big problem for the
analysis of antigen-specific T cell responses. The analysis of T cell responses under in
vitro or in vivo conditions is a special case for "immune monitoring". The frequency
of naive peripheral T cells against a given antigen has been estimated between 4 x
10−8 and 2 x 10−5 [63–65] but may increase during T cell responses up to 6 x 10 −1
among CD8+ T cells [66]. Any ideal T cell assay would be a direct assay covering this
full dynamic range with high linearity. Furthermore, one has to think about different
functionalities and pathways of activation between naive, effector, and memory T cells.
One may divide T cell assays into functional versus specificity assays. Definition of
standards for T cell assays is difficult. Nevertheless, the use of commonly occuring
antigens and the generation of T cell clones specific for positive control antigens such
as cytomegalovirus and influenza may provide standards for determining the accuracy
of T cell methodologies to be evaluated. A reliable method to measure T cell responses
should be able to maintain accuracy, precision, sensitivity, and specificity despite changes
in external factors such as technicians, instruments, or reagents.
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1.7.2 Functional T cell assays
Effector or memory T cells respond by exerting an "effect" after they got in contact with
antigen presented on MHC complexes which are expressed by target cells. Such effects
may be proliferation, cytokine expression, expression of activation markers, degranula-
tion, target cell cytotoxicity and/or trogocytosis. A very important in vitro parameter
for in vivo function is T cell proliferation. The proliferation of T cells in response to in
vitro stimulation is commonly determined by a radioactive method which is based on in-
corporation of [3H] thymidine or 5-bromo-2´-deoxyuridine (BrdU) into newly generated
DNA [67]. This method is widely applied but has some disadvantages. First, the method
requires radioactive facilities. Additionally, this technology gives only information on the
overall proliferative responses, but does not give any information about the specific cell
subsets involved in these responses. Alternative methods to measure T cell proliferation
are the assessment of CD38 expression on T cells analyzed by flow cytometry and an
enzyme-linked immunosorbent assay (ELISA). Furthermore, it is possible to prelabel
cells with a stable covalent dye, such as 5,6-carboxylfluorescein diacetate succinimidyl
ester (CFSE) [68]. After each cell division, in response to antigen recognition, CFSE
content will be approximately reduced by 50% and could be measured directly by flow
cytometry. A variety of cytokine expression assay have been reported up to now for
the detection of antigen-specific cells. All these assays can be performed specifically for
different cytokines, depending on the expected functionality of the cells. Thereby, the
most important cytokine for the detection of activated CD8+ or CD4+ T cell responses
is IFN-γ. Bulk cytokine expression assays on a protein level are classic sandwich enzyme
linked immunosorbent assays (ELISAs) [69] or similar protein detection assays such as
the cytometric bead assay [70], which allow simultaneaius or "multiplexed" detection
of several cytokines within one sample. On mRNA level, quantitative real time poly-
merase chain reaction (qRT-PCR) has been exploited as a sensitive method to detect
antigen-specific T cells, based on the principle that amplification of cDNA by poly-
merase chain reaction follows a strict mathematical equation whereby with each cycle
of amplification two copies are made from each individual oligonucleotide species [71].
For single based cytokine assays, three methods exist:cytokine capture [72] assay, en-
zyme linked immunospot (ELISpot) assay [73, 74] and intracellular cytokine staining
[75]. In cytokine caption assays, cells are labeled before hand with a "capture matrix",
i.e. anti-cytokine antibodies non covalently coupled to the cell surface. After stimula-
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tion, secreted cytokines are captured on the cell surface and can be later szained with
fluorescently labeled second anti-cytokine antibody. This method can be combined with
live cell sorting, this is due to the undestructive nature of this method. The ELISpot
assay is nearly similar to ELISA but on a single-cell level. A nitrocellulose-bottomed
microtiter plate is non covalently linked to an antibody that binds the cytokine of inter-
est. Antigen-specific T cells, either unseparated PBMCs or CD8+ or CD4+ T cells are
incubated in the plate together with the antigen to test. Upon stimulation recognition of
the antigen leads to release of cytokine of interest, which is then bound by the antibody
coated on the plate and forms small "invisible" spots on the membrane. Cytokine release
is visualized after removal of the cells by an enzyme-linked second anti-cytokine antibody
and a corresponding chromogenic substrate which has to be non-soluble to precipitate at
the bottom of the well. Cytokine secreting T cells become visible as colored spots. Col-
ored spots can be counted by a computer system. The assay detects only T cells that
are preactivated in vivo, since naive T cells do not secrete cytokines upon shortterm
stimulation. Thus, the ELISpot assay is useful to measure number and functionality
of antigen-specific T cells ex vivo. Intracellular cytokine staining is based on direct de-
tection of intracellular cytokine expression with fluorochrome-conjugated anti-cytokine
antibodies after short periods of activation with antigens. Cytokines are usually rapidly
secreted and diffuse away from the secreted cell. While performing intracellular cytokine
staining, cells are incubated during antigen challenge with specific inhibitors (most often
Monensin or Brefeldin A) that are able to block cellular secretory pathways and lead
to an intracellular enrichment of the cytokine. After staining with surface markers like
anti-CD8 or anti-CD4, cell membranes are permeabilized using non-ionic detergents, fol-
lowed by intracellular staining of cytokine of interest and fixation of the cells. The assay
can be performed with PBMCs [76], whole blood [77, 78], lymph nodes, or other biologic
fluids. Therefore, a total incubation period of 6 hours is optimal for achieving high lev-
els of cytokine-secreting cells for IL-2, IL-4, IFN-γ, and TNF-α, as well as for achieving
maximal cytokine staining intensity [77]. Activated T cells express proteins which are
not found on resting T cells. Common activation markers are: CD69, CD25 and HLA-
DR (in human T cells). Single-cell assays have been employed that use flow cytometric
staining of the surface markers on activated T cells [79]. Disadvantages of this method
are narrow, distinct time windows in which the molecules are expressed and the fact that
these surface markers are also found on subpopulations of ex vivo isolated T cells in the
absence of antigen [80]. Antigen-specific cytotoxic T cells (CTLs) can be detected by
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degranulation. Activation of CTLs leads to the fusion of cytotoxic granula with the cell
membrane followed by release in the extracellular environment. Proteins like CD107a/b
which are normally found on the membrane of the granula, become transiently located
to the cell membrane. This effect is strongly associated to cytotoxicity and can be used
to detect and sort antigen-specific CD8+ T cells [81] by a single-cell based assay that
employs staining cells during and after activation with fluorescent anti-CD107a/b anti-
bodies and flow cytometry. Another effect of functionality of activated CD8+ T cells is
the ability to lyse target cells. The first described method for the detection of CTLs is
the 51Chromium-release assay (CRA) [82, 83] which can be performed either on fresh
cells [Plata, 1987; Walker, 1987; Riviere, 1989] by measuring effector CTL activity, or on
CTL lines [Walker, 1987; Nixon, 1988] by evaluating memory CTL activity. Target cells
are labeled by a radiochemical compound, with 51Cr(VI)O42−, which is able to enter
cells through anion transport systems. In the cytoplasm it is subsequently reduced to
51Cr(III). As Cr(III) will reside inside the cell, cellular accumulation of 51Cr is greatly
facilitated [84]. Labeled target cells are incubated with effector cells (CD8+ T cells) for
several hours. When cytotoxicity occurs, 51Cr will be released from the target cell and
becomes detectable in the supernatant. This assay is very useful for the determination
of direct cytotoxicity of T cells but is inadequate for ex vivo studies that require the
quantification of antigen-specific CD8+ T cells in a mixed lymphoid population. Trogo-
cytosis is an only recently described phenomenon of all lymphocytes. Within minutes
surface material from the antigen presenting cell to the effector cell is transferred during
formation of a biological synapse. But the mechanism and biological function of this
effect are still not clear [175]. However, it has been already exploited to detect antigen
presenting CD8+ T cells [85, 86]. For auch an assay target cells have to be engineered by
coupling green fluorescent protein (GFP) to the cognate HLA molecule. When pulsed
with antigen and coincubated with HLA antigen-specific T cells, these aquire HLA-GFP
from the target cell and become fluorescent and thus detectable by flow cytometry.
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1.7.3 Specificity assays
Oppositional to their functionality, antigen-specific T cells can be detected solely by the
presence of the cognate T cell receptor on their cell surface. For a quantification of
antigen-specific T lymphocytes with regard to their specificity the analysis via labeled
multimeric MHC:peptide complexes (also called tetramers) [87] is useful. These are
capable of identifying and enumerating antigen-specific T cells and also provide func-
tional information when combined with other methodologies. Tetramers are prepared
by in vitro folding MHC heavy chain in the presence of β2-microglobulin and a specific
peptide ligand. Purified MHC/peptide monomers are multimerized via streptavidin, an
avidin-like protein from Streptomyces avidinii which has four binding sites for biotin with
very high affinity [88], to form soluble tetrameric complexes (Figure 1.5). MHC/peptide
tetramers will bind T cells bearing MHC/peptide-specific T cell receptors and can be
detected by flow cytometry (Figure 1.5). Moreover, phenotypic characterization of cells
detected by tetramer staining is enabled by possible parallel detection of co-expressed
cell surface antigens [89]. During the last years, multimeric MHC/peptide reagents have
shed a new light on T cell responses, as they offered for the first time a window to the
whole T cell response against a given T cell epitope, independent of function, but there
are also some limitations. First, MHC/peptide tetramers stably bind to TCR exhibiting
a certain minimal avidity. Hence, functional T cells may be missed in this assay depend-
ing on the staining conditions, e.g. temperature [90–92] or concentration of tetramers.
Moreover, MHC/peptide tetramers also interact with the CD8/CD4 co-receptor and
may therefore influence binding of anti-CD8 antibodies [93, 94] what may lead to pep-
tide independent binding and ultimately false positive results. Secondly, MHC/peptide
tetramers are also known to bind other receptors such as killer cell immunoglobulin-like
receptors (KIRs) or immunoglobulin-like transcripts (ILTs) expressed on natural killer
cells [95–97].
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Figure 1.5: Tetramer analysis to detect T lymphocytes (T cells) that have spe-
cific T cell receptors on their cell surface.
(a) Soluble versions of the heavy chain of major histocompatibility complex (MHC)
class I molecules are synthezised in Escherichia coli bacteria. (b) The molecules adopt
an appropriate conformation following the addition of β2 microglobulin (β2m) and a
synthetic peptide that represents the epitope that is recognized by the T cell receptor
(TCR) of interest. This peptide is able to bind to the MHC molecule. In addition, the en-
zyme BirA is used to attach a biotin molecule to the specific BirA-recognition sequence,
which has been incorporated into the carboxyl terminus of the MHC molecule. (c) Four
MHC-biotin complexes are linked to a single streptavidin molecule, using the specific
biotin-avidin interaction, to form a tetramer. The streptavidin molecule is ’tagged’ with
a fluorochrome (e.g. phycoerythrin; PE). (d) Tetramers are mixed with the cell pop-
ulation that is to be analyzed (e.g. total peripheral blood mononuclear cell (PBMC)
populations or CD8+ T lymphocytes (T cells)). Only T cells that have TCRs that are
capable of binding to the particular MHC:peptide combination that is present in the
tetramer are able to bind the tetramer; thus, such cells will become labelled with the
PE fluorochrome (shown in red on the graph in (e)). A monoclonal antibody that is
specific for a T cell marker and is tagged with a different fluorochrome (e.g. fluorescein
isothiocyanate (FITC), shown in green) can also be used. (e) The cells are then ana-
lyzed using flow cytometry; the proportion of the CD8+ T cell population that stains
positively with the tetramer can be determined (top, right-hand quadrant)
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1.7.4 In vitro stimulation of antigen-specific T cells
Using antigen-specific T cells in adoptive immunotherapy requires injection of large
amounts of previously amplified antigen-specific T cells. Classically, expansion of naive
T cells is achieved by using in vitro derived professional antigen-specific cells, such as
autologous monocyte derived dendritic cells [98] or autologues activated B lymphocytes
[99]. It is important to separate T cells specific for an antigen of desire out of a whole
T cell population, therefore it is possible to stimulate and amplify T cells either in an
antigen-independent manner or by stimulation with specific antigen. Mixed T cell pop-
ulations can be separated using fluorescence activated- or magnetic-affinity cell sorting
(FACS/MACS) systems [87, 100–102] or populations can be cloned by limiting dilution
[103]. Antigen independent amplification of T cells can be achieved using polyclonal mi-
togens or stimulatory antibodies, usually in combination with cytokines like IL-2 [104].
Several antibodies able to support T cell stimulation are known, e.g. anti-CD3 [104]
or antibodies directed against costimulatory antigens such as CD28 [105], 4-1BB [106]
or CD27 [107, 108], respectively. Polyclonal mitogens can be concanavalin A (Con A)
[109] or phytohaemagglutinin (PHA) [110]. For stimulation and proliferation of antigen-
specific T cells in vitro several approaches can be used. However, the use of autologous
professional antigen presenting cells is hampered by the fact that current methods for
theit isolation/generation are expensive, time-consuming, difficult to standardize and
can only yield relatively low cell numbers. Different groups tried to overcome these
limitations by using artificial antigen presenting cells (aAPCs), like allogeneic tumor
cells, e.g. K562, which could be transfected with costimulatory and adhesion molecules,
such as CD80, 4-1BBL, LFA-3 and ICAM-1 [111]. Possible effects of allostimulation are
avoided by transfection of single peptide-HLA complexes into HLA-deficient cells [208].
A different approach relies on the use of isolated recombinat MHC/peptide complexes
(monomers). These complexes are coated on a surface, which can be lipid vesicles[112],
plastic microspheres [113, 114], or even HLA-deficient cell surfaces [102].
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1.8 The Human Cytomegalovirus (HCMV)
1.8.1 Cytomegalovirus and the Immune system
The human cytomegalovirus (HCMV) is a member of the β-herpesvirus family which
is characterized by its strict host specificity. It provokes an acute infection followed by
a lifelong persistence of the virus in the human organism with episodes of endogenous
reactivation [23]. HCMV-infected cells typically become enlarged (cytomegalia) [115]
and eventually develop nuclear and cytoplasmic inclusions that are characteristic for
HCMV infection. In vivo the virus targets a wide variety of cells including epithelial
and endothelial cells, fibroblasts, smooth muscle cells, and peripheral blood leukocytes,
which include monocytes and granulocytes [115]. Furthermore, there is intrauterine
(congenital infection), perinatal (cervix secretions) and postnatal (breast milk) virus
transmission, [116–119] which occurs also by saliva and sexual contact [120]. HCMV
infection is common worldwide. The prevalence increases continuously after the child-
hood. In developed countries 10% - 20% of all children and 40% - 100% of adults
are HCMV-seropositive [121] whereas the status in developing countries is much higher
[121]. HCMV infection rarely causes symptomatic disease in healthy, immunocompetent
individuals but manifests itself as a lifelong persistent infection. Evidences for a major
role of T cells in the immune control of this persistent infection are provided by the
uncontrolled viral replication and HCMV end-organ diseases observed in immunocom-
promised individuals with severely impaired T cell functions like transplant recipients
or AIDS patients [122, 123]. Thus, the virus appears to be a major cause of morbid-
ity and mortality in immunocompromised persons. The reactivation of HCMV in these
patients leads to a variety of maladies such as HCMV-associated pneumonitis, retinitis
pneumonia [124, 125] as well as gastro-intestinal erosions and ulcer [126–128]. Further-
more, severe aetiopathology are described in children infected intrauterine [129–131].
Congenital infection is associated with a range of clinical manifestation, but relatively
few infected infants are severely ill at birth. In many, the signs and symptoms may be
subtle or non-specific during the newborn period and during early childhood, even as the
child experiences progressive hearing damage and as serious consequences of infection,
including mental retardation, cerebral palsy, and impaired vision become apparent [132].
After primary HCMV infection CMV IgM antibodies are produced before IgG antibodies
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and persist for a few months. HCMV IgG antibodies are produced after secondary and
primary infections and persist lifelong [133]. This persistence is the reason hat IgG
antibodies are used as a sign that the patient had an HCMV infection in the past. Both
innate and adaptive arms of the immune response are of importance for the control
of HCMV infection. The importance of the humoral immunity is suggested by the
clinical observation that without humoral immune response the patient will not clear
the virus. Within the adaptive immune response, both T cells and antibodies have
been shown to protect from acquisition of HCMV or from serious disease in different
settings [134–136]. Another argument for a role of antibodies in the clearance of the
virus is the effectiveness of prophylactic administration of CMV immunoglobulin in
seronegative recipients of kidneys from seropositive donors in preventing morbidity and
mortality associated with HCMV [137, 138]. The importance of the humoral immune
response is also demonstrated by the finding that HCMV-specific antibodies reduce the
generation of pp65 positive granulocytes by inhibiting uptake of pp65 by granulocytes
from infected endothelial cells in vitro [139]. Nevertheless, antibodies are not typically
sufficient to control HCMV infection. The cellular immune response by CD4 helper T
lymphocytes, CD8 cytotoxic lymphocytes and Natural Killer (NK) cells are the most
important adaptive immune components. [140–142]. The production of IFNγ by NK
cells facilitates the expansion of antigen-specific TH cells which are critical for HCMV
control [122, 143]. During initial infection, the frequence of HCMV-specific CD8+ T
cells raises to a very high level. After suppression of viral replication many of HCMV-
specific T cells die, but compared to other common viral pathogens, the numbers of
circulating T cells that recognize HCMV peptides remain quite high [144, 145]. HCMV-
specific HLA class I-restricted T cell responses are known to be essential for successful
resolution of the infection and maintenance of long-term control of HCMV replication
[53, 146–148]. Two HCMV proteins serve as key target antigens for HCMV-specific T
cells: a late matrix protein (pp65; UL83) that is abundant throughout HCMV infection
and an immediate early 1 (IE1; UL123) antigen protein that is indispensable for viral
replication [149]. For a certain time IE1 was not considered a relevant target because
reports had suggested that it was not efficiently presented on MHC class I after infection
[51]. By contrast, virion proteins were known to be presented even in the absence of
viral replication [150], and additionally, pp65 itself was found to interfere with IE1
presentation [151]. Therefore, research focussed on pp65 for several years [152, 153].
In 1999, IE1 became again of interest as a T cell target after IE1-specific CD8+ T
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cells were detected in infected individuals at frequencies at least comparable to those
of CD8+ T cells specific for pp65 [154]. To date, both pp65 and IE1 are considered
dominant T cell targets [155, 156]. All in all, many of the antigen-specific CD8+ T
cells recognize peptides of the pp65 or IE1 protein, although the spectrum of antigen
recognition may include other viral proteins [157, 158]. HCMV can not be eliminated
by the host immune response, although the titer of the virus in the mucosa and the
peripheral blood is reduced and the virus becomes undetectable persistence and latency
are established. Cytomegalovirus has developed several mechanisms to evade cellular
immune response [159, 160]. For example the virus can prevent HLA class I loaded with
viral peptides to be delivered to the cell surface. This makes the infected cell invisible
to CD8 cytotoxic T lymphocytes. Also the virus encodes a glycoprotein homologous to
class I MHC antigens to prevent attack by NK cells. The characterization of the immune
response against HCMV turns out to be quite difficult because most HCMV infections are
asymptomatic making it impossible to examine the early phases of host response to the
virus [161]. HCMV has been associated with increased subsequent risk for acute rejection
in kidney and other solid organ transplant recipients [162]. Whether the risk is conferred
by the reduction of immunosuppressive medication used to treat HCMV infection or is
a direct immunomodulating effect of the virus, is not known. However, experiments
in immunocompromised bone marrow transplant recipients [53, 163–165] demonstrate
that CMV-specific cell-mediated immunity is essential to control the disease. The innate
immune response may augment the adaptive immune response, and the magnitude of the
initial adaptive immune response is important in determining the numbers of antigen-
specific memory T cells.
1.8.2 Vaccine strategies against HCMV
The development of vaccines against infectious agents are one big feature of immunology
and are of high success in diseases such as polio, measles, hepatitis B and tetanus [166].
Anyhow, many infectious agents still evade the immune system and lead to severe infec-
tions. HCMV is still a cause of mononucleosis in immunocompetent individuals and is
a well-known cause of serious morbidity and sometimes fatal infections in immunocom-
promised patients especially recipients of solid-organ or hematopoetic cell allografts and
individuals with advanced AIDS [167, 168]. Antiviral drugs have constituted an impor-
tant advance for prevention or resolution of HCMV infections especially with regard to
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early posttransplant time. Nevertheless, long-term control of the persistent virus in the
host will depend on the ability to raise an adequate immune response to the perspective
pathogen. CD8+ and CD4+ αβ-T cells provide an immunologic memory response which
may have major significance with regard to protective immunity to cytomegalovirus in-
fection [169]. A model with murine cytomegalovirus (MCMV) suggests a critical role of
αβ-T cells in HCMV infection. Although MCMV is genetically distinct from HCMV, the
pathogenesis of infection in immunosuppressed mice is similar to that for human CMV
[170, 171]. Several methodologies were developed for determining antigen-specific T cells,
e.g. intracellular cytokine staining or staining with tetrameric MHC class I/peptide com-
plexes. These have further confirmed the role of HCMV-specific T cells in controlling
HCMV infection - in healthy HCMV-seropositive individuals, up to 40% of all T cells
in the peripheral blood can be specific for HCMV [172] emphasizing the importance
of a strong HCMV-specific cellular immunity in persistent HCMV infection. Moreover,
strategies to isolate and expand clonal populations of αβ-T cells with defined specificity
for viral antigens became well-established and support adoptive cellular immunotherapy.
For adoptive cellular immunotherapy, CD8+ HCMV-specific T cell clones were cultured
in vitro by cyclic stimulations of the T cells in presence of donor-derived γ-irradiated
feeder cells and Interleukin-2 (IL-2) to promote numeric expansion. Clones that were
αβ-TCR+, CD3+, CD8+, and CD4−, and recognized epitopes derived from structural
virion proteins and presented by MHC class I were selected for intravenous administra-
tion to the recipient [173]. This first study on adoptive transfer has proved safety and
effectiveness of the method to restore CD8+ HCMV-specific cytotoxic T cell immunity.
A very promising strategy to expand HCMV-specific CTLs for allogeneic applications
from cord blood, is described by Park et al., [174]. Another setting uses dendritic cells
which are pulsed with peptide or protein, or HCMV-specific CD4+ T cells [52] to induce
HCMV-specific CD8+ T cell responses for the treatment of HMCV infection. Further-
more, genetically modified T cells are used for adoptive immunotherapy offering the
potential to be safe and efficient [175]. As described above, protective responses to in-
fectious agents like HCMV rely largely on T cells. Therefore, not only adoptive transfer
of T cells is an approach for antiviral immunotherapy. Also the use of a peptide-based
vaccine may be in focus of discussion.
24
General Introduction
1.9 Aims of the thesis
As peptide-based immunotherapy is restricted by many different HLA-types of patients
it was important to identify T cell epitopes with distinct HLA restrictions. Current
strategies require the time consuming generation of antigen presenting cells (APCs),
usually dendritic cells (DCs), for stimulation protocols. One aim of this thesis was the
development of a method for fast and reproducible in vitro priming and expansion of
CD8+ T cells specific for peptides from tumor-associated antigens. To achieve this goal,
T cell priming experiments with artificial antigen presenting cells (aAPCs), coated with
different amounts of costimulatory molecules and HLA-peptide complexes, as well as
experiments to analyse the specificity and functionality of the induced T cells, were per-
formed. Using aAPCs coated with only one costimulatory antibody (anti-CD28) and
one HLA-peptide complex for in vitro priming of cytotoxic T cells, which was estab-
lished and published by Steffen Walter et al.; we tried to further improve this promising
method by using a second costimulatory molecule (anti-4-1BB) coated on the surface of
the aAPC. Therefore different titration assays had to be performed in order to find the
optimal condition for this priming strategy.
HCMV is a cause of severe diseases in immunocompromised individuals such as trans-
plant recipients or AIDS patients, therefore it is very important to search for new op-
portunities in vaccine development sich as adoptive transfer of HCMV-specific T cells.
Nevertheless, a major limitation of adoptive immunotherapy is the availability of HCMV-
specific CTLs in HCMV seronegative blood donors. Thus, this thesis also aimed at the
induction and expansion of HCMV-specific CD8+ T cells from the blood of HCMV-
seronegative donors. Priming experiments performed with the help of artificial aAPCs
coated with costimulatory antibodies and HLA-peptide complexes lead to successful in
vitro primimg of HCMV-specific T cells, which would be a great progress in the treat-
ment of HCMV infection.
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2 Results and Discussion, Part 1: Artificial antigen
presenting cells - a highly capable resource for
priming of antigen-specific CD8+ T cells
2.1 Potent costimulation of human CD8 T cells by anti-4-1BB
and anti-CD28 on synthetic artificial antigen presenting cells
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2.1.1 Abstract
The in vitro generation of cytotoxic T lymphocytes (CTLs) for anticancer immunother-
apy is a promising approach to take patient-specific therapy from the bench to the
bedside. Two criteria must be met by protocols for the expansion of CTLs: high yield
of functional cells and suitability for good manufacturing practice (GMP). The antigen
presenting cells (APCs) used to expand the CTLs are the key to achieving both targets
but they pose a challenge: Unspecific stimulation is not feasible because only memory
T cells are expanded and not rare naïve CTL precursors; in addition, antigen-specific
stimulation by cell-based APCs is cumbersome and problematic in a clinical setting.
However, synthetic artificial APCs which can be loaded reproducibly with MHC-peptide
monomers and antibodies specific for costimulatory molecules could resolve these prob-
lems. The purpose of this study was to investigate the potential of complex synthetic
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artificial APCs in triggering the costimulatory molecules CD28 and 4-1BB on the T cell.
Anti-4-1BB antibodies were added to an established system of microbeads coated with
MHC-peptide monomers and anti-CD28. Triggering via CD28 and 4-1BB resulted in
strong costimulatory synergy. The quantitative ratio between these signals determined
the outcome of the stimulation with optimal results when anti-4-1BB and anti-CD28
were applied in a 3:1 ratio. Functional CTLs of an effector memory subtype (CD45RA−
CCR7−) were generated in high numbers. We present a highly defined APC platform
using off-the-shelf reagents for the convenient generation of large numbers of antigen-
specific CTLs.
2.1.2 Introduction
CD8 T cells are key effectors in the battle against viral pathogens. In cancer immunology,
they help to fight tumor cells. Many tumor-associated T-cell epitopes have been defined
and this has enabled the design of highly specific anti-cancer regimens [1]. Due to the
lack of functional tumor-specific cytotoxic T lymphocytes in many cancer patients, there
is a need for the development of methods to prime and expand tumor-specific CTLs.
Adoptive immunotherapy is an approach which involves in vitro priming and expansion
of T lymphocytes with subsequent in vivo infusion of expanded CTLs. Dendritic cells
have been used as APCs for the in vitro priming of CTLs [2]. This method involves the
laborious differentiation of autologous peripheral blood monocytes or CD34+ hematopoi-
etic precursors. A problem of this strategy is the limited number of dendritic cells that
can be generated. Furthermore, only dendritic cells which are fully mature can prime
T cells; immature dendritic cells induce tolerance [3]. The advent of artificial APCs has
raised hopes that these shortcomings might soon be overcome. Many different artificial
APCs have been designed-either cell-based or synthetic artificial APCs. First, artificial
APCs were developed for the unspecific expansion of T cells. These approaches took ad-
vantage of anti-CD3 and anti-CD28 antibodies which were added to T cells [4] and used
to decorate cell lines such as K562 [5] or microbeads [6]. However, these methods are
unsuitable for anti-cancer immunotherapy when rare precursor T cells need to be primed
and expanded in an antigen-specific fashion. Thus, methods for antigen-specific T cell
priming and expansion have been established. Various examples of cell-based strategies
have been presented: they include HLA-A2-negative B cells loaded with HLA-A2 MHC-
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peptide monomers [7], mouse fibroblasts retrovirally transduced with an HLA-peptide
complex plus the accessory proteins B7.1, ICAM-1, and LFA-3 [8] and insect cells trans-
fected with single-chain HLA, CD54 and CD80 [9]. These protocols have shown that
the generation of antigen-specific T cells by employing artificial APCs is feasible. How-
ever, the use of such artiWcial APCs in a GMP setting is problematic because cellbased
reagents are difficult to implement in GMP protocols. In contrast, synthetic artificial
APCs, which are made from a limited number of "off-the-shelf" components, could be
more suitable for the clinic. Previous studies have established protocols that involve mi-
crobeads loaded with MHC-peptide molecules in monomeric [10] or Ig-coupled dimeric
forms [11], and anti-CD28. Clearly, the engineering of artificial APCs is not only a
qualitative problem (in terms of the receptors on the T cell to be triggered) but also
a quantitative challenge since APCs in vivo display a carefully controlled expression
pattern of costimulatory molecules. This issue was neglected during the design of cell-
based artifical APCs when cell lines were engineered to express different costimulatory
molecules (see above).To address these issues, we hypothesized that the use of further
stimulatory antibodies in addition to anti-CD28 could render synthetic artificial APCs
more powerful, especially if the stimulatory signals were applied in an optimised ratio.
To demonstrate this, we took advantage of a strictly controlled system of microbeads
loaded with defined amounts of MHC-peptide monomers and anti-CD28 antibodies that
was previously used to prime and expand CTLs [10, 12]. To assess possible synergistic
effects between costimulatory antibodies, anti-4-1BB was added to the system in the
present study. This antibody triggers the tumor necrosis factor (TNF) receptor family
member 4-1BB (CD137) [13]. Its ligand 4-1BBL is expressed by APCs such as acti-
vated B cells and dendritic cells [14]. The costimulatory molecule 4-1BB is upregulated
within 24 h after T cell activation [15] and signals independently from CD28 [16]. 4-1BB
signalling primarily induces CD8 T cell proliferation in vitro and leads to the amplifi-
cation of cytotoxic T cell responses in vivo [17]. 4-1BB was characterized as a T cell
survival signal [18] which may be due to its anti-apoptotic effects [19]. Several studies
have shown anti-tumor and antiviral effects of 4-1BB costimulation [20–23]. 4-1BBL
was demonstrated to be a valuable costimulatory factor for the unspecific expansion of
T cells via anti-CD3 and anti-CD28 [24, 25]. In this study, we found a synergy between
anti-CD28 and anti-4-1BB antibodies during T cell priming and expansion that was
dependent on the antibody ratio; we report the highest percentage of peptide-specific
CTLs generated by antigen-specific in vitro priming so far. The CTLs displayed an eVec-
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tor memory phenotype and were functional, thereby proving their value for therapeutic
approaches. An effective protocol for the in vitro generation of CTLs is provided and
the importance of highly defined, synthetic artificial APCs is highlighted.
2.1.3 Material and Methods
Peptides and MHC-peptide monomers
The Melan-A-derived peptide ELAGIGILTV [26] was synthesized using standard Fmoc/tBu
chemistry [27]. Biotinylated recombinant HLA-A∗0201 molecules and fluorescent MHC-
tetramers were produced as described previously [28]. Briefy, fluorescent tetramers
were generated by incubating biotinylated HLA monomers with streptavidin-PE or
streptavidin-APC (Molecular Probes, Leiden, The Netherlands) at a 4:1 molar ratio.
Biotinylated antibodies
The antibodies mouse IgG2a anti-human CD8 Ab OKT-8, mouse IgG2a anti-human
CD28 Ab 9.3, mouse IgG1 antihuman 4-1BB Ab 4B4-1 (Becton Dickinson Biosciences
(BD), Heidelberg, Germany) or [29] were biotinylated using sulfo-N-hydroxysuccinimidobiotin
(Perbio Science, Bonn, Germany) as recommended by the manufacturer.
Synthetic artificial APCs
About 5.6 µm-diameter streptavidin-coated polystyrene particles (BangsLabs, Fishers,
IL, USA) were resuspended at 4 x 106 microbeads per ml in PBE (PBS/BSA/EDTA) was
PBS (phosphate-buffered saline) (BioWhittaker, Verviers, Belgium) containing 0.5% of
bovine serum albumin (Sigma, Aldrich) and 2 mM EDTA (Roth, Karlsruhe, Germany),
containing 200 pM biotinylated MHC-peptide monomer and a total antibody concen-
tration of 20 nM and incubated at room temperature for 30 min. After washing, the
synthetic artifcial APCs were stored at 4◦C prior to use.
In vitro priming and expansion of human CD8 T cells
Fresh HLA-A∗02+ buffy coats or leukapheresis products were used to isolate PBMCs by
standard gradient separation. CD8 T cells were MACS-enriched by biotinylated OKT-8
antibody and Streptavidin-Microbeads (Miltenyi-Biotec, Bergisch-Gladbach, Germany).
Stimulations were initiated in 96-well plates with 1 x 106 responder cells plus 2 x 105
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microbeads in 250 µl of T cell medium [10] complemented with 5 ng/ml human IL-12
p70 (PromoKine,Heidelberg, Germany). After 3-4 days of incubation at 37◦C, fresh
medium with 80 U/ml human IL-2 (Chiron, Emeryville, CA, USA) was added and cells
were incubated for another 3-4 days. This stimulation cycle was performed three/four
times.
CFSE-based proliferation assay and cloning
To evaluate the proliferative response to the MelanA antigen, 70 x 106 CD8+ T cells were
labeled with 5µM CFSE (5/6-carboxyXuorescein diacetate, succinimidyl ester, Molec-
ular Probes, Leiden, The Netherlands) and incubated for 10 min at 37◦C in the dark.
To stop labeling, an equal volume of T cell medium complemented with 20% heat-
inactivated fetal bovine serum (FCS) (PAA, Cölbe, Germany) was added for another 20
min. Cells were then washed in T cell medium four times. About 106 CFSE-labeled cells
were seeded into individual wells of a 96-well culture plate, synthetic artificial APCs were
added as indicated. CD8+ T cells were incubated at 37◦C, 5% CO2. Antigen-stimulated
CFSE labeled CD8+ T cells were analyzed by flow cytometry on a four-color FACSCal-
ibur cytometer (BD).
Flow cytometry
Tetrameric analyses were performed with tetramer-PE/APC plus antibody CD8 PerCP
clone SK1 (BD). Cells were incubated with the antibody at 4◦C for 20 min in the dark,
followed by 30 min incubation with fluorescent MHC tetramers at the same conditions.
After washing, cells were analyzed by flow cytometry on a four-color FACSCalibur cy-
tometer (BD). Total specific cell numbers per sample could be calculated after FACS
analysis: (specific cells counted) x (microbeads added)/(microbeads counted). For phe-
notyping CCR7 staining was performed using rat hybridoma supernatant 3D12 (kindly
provided by R. Förster, Anova) and donkey anti-rat (Fab´)2-PE fragments (Jackson
ImmunoResearch, West Grove, PA, USA) or hCCR7 PE (R&D, Wiesbaden, Germany).
After blocking with 10% heat-inactivated mouse serum (CC pro, Neustadt, Germany),
cells were further stained with CD45RA-FITC (BD) and tetramer-APC. Analysis of sur-
face costimulatory molecules, CD137 (4-1BB) and CD28 staining was performed using
anti-human CD137-PE (BD) and anti-human CD28-FITC (Immunotools, Friesoythe).
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Generation of T cell lines
Sorting was done with a FACSVantage cell sorter. Sorted tetramer-positive cells were
expanded by PHA-L, IL-2, and feeder cells (irradiated LG2-EBV and irradiated allo-
geneic PBMCs) as described before [10].
T cell assays
Intracellular IFN-γ staining was done as previously described [23]. Briefly, T cells were
stimulated with 10 µg/ml peptide for 6 h in the presence of Golgi-Stop (BD). Cells were
analyzed using a Cytofix/Cytoperm Plus kit (BD) and an IFN-γ-PE or IFN-γ-FITC
antibody (BD). After staining, cells were analyzed on a four-colour FACSCalibur (BD).
Cytotoxicity was tested in a standard 4 h 51Cr release assay using 3,000 target cells
per well. Percentage of specific lysis was calculated as follows: (experimental release -
spontaneous release)/(total release - spontaneous release) x 100.
2.1.4 Results
Synergy between anti-CD28 and anti-4-1BB in CD8 T cell costimulation is most
pronounced when applied in a specific ratio To assess the stimulative capacity of
anti-CD28, anti-4-1BB and a potential synergy of the antibodies, beads were coated
with MHC-peptide-monomer and loaded either with a single antibody or with both
antibodies at different ratios. First, the proportion of antigen-specific CTLs prior to
stimulation was determined by flow cytometry (Fig. 2.2 A): in an ideal setting with a
purity of 100% CD8+ enriched T cells, 0.1% antigen-specific CTLs correspond to a total
number of 1,000 antigen-specific CTLs per well (106 CD8-enriched cells were used per
well). After three rounds of stimulation, moderate T cell priming and expansion were
detected with a single costimulatory antibody (Fig. 2.1 A). However, combining both
antibodies resulted in a higher percentage of tetramer-positive cells. A 3:1 ratio between
anti-4-1BB and anti-CD28 increased the percentage of tetramer-positive cells to values of
up to 48% after three rounds of stimulation. In the experiment shown in Fig. 2.1a, about
147,000 tetramer-positive CTLs were detected using the optimal 3:1 ratio of the costimu-
latory antibodies compared with an average of 21,000 CTLs when using anti-CD28 only.
in vitro stimulation of CD8+ T cells from six other healthy donors confirmed that a ratio
of 3:1 of anti-4-1BB to anti-CD28 was superior to anti-CD28 alone (Fig. 2.1 A inset):
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on average, a fivefold higher percentage of specific CTLs was obtained. When either
anti-CD28 or anti-4-1BB were replaced by an isotype control, no synergistic effect was
observed (data not shown). Thus, any effects due to antibody dilution could be excluded.
Figure 2.1: Anti-CD28 and anti-4-1BB on MHC-coated microbeads synergize
in T cell priming and expansion.
Quintuplicates of CD8-enriched T cells of a healthy HLA-A2-positive donor were stim-
ulated three times (A) or four times (B) in vitro with A∗0201/ELAGIGILTV-coated
microbeads loaded with either anti-CD28, anti-4-1BB or a combination of both. Posi-
tive T cells were detected by tetramer staining. Repeated stimulation of CD8-enriched
T cells of different donors demonstrated that on average a fivefold higher percentage of
tetramerspecific T cells can be obtained by costimulation with anti-4-1BB/anti-CD28 in
a 3:1 ratio if compared to anti-CD28 alone
(inset Fig. 2.1 A)
Elevated levels of antigen-specificc CTLs after four rounds of stimulation
Usually three rounds of stimulation are performed during in vitro priming. Here, we
demonstrate that a further round of stimulation can result in a much higher percentage
of antigen-specific cells. For the optimal ratio between anti-CD28 and anti-4-1BB, values
of up to 72% antigen-specific T cells were monitored (Fig. 2.1 B).
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To our knowledge this is the highest value of antigenspecific cells observed for in vitro
priming experiments.
Figure 2.2: Highly elevated levels of antigen-specific effector memory CTLs
after stimulation.
(A) PBMCs of a healthy HLA-A2-positive donor were stained ex vivo with CD8-
PerCP and tetramer to detect the frequency of antigen-specific T cells before stim-
ulation. Due to unspecific tetramer binding to B cells, only CD8+ cells are shown.
(B) CD8-enriched T cells of the same donor were stimulated four times in vitro with
A∗0201/ELAGIGILTV-coated microbeads loaded with anti-CD28 and anti-4-1BB in a
1:3 ratio. Positive T cells were detected by tetramer staining. (C) T cells were stained
with CD8-PerCP, CD45RAFITC, CCR7 (rat hybridoma supernatant and donkey anti-
rat-PE) and tetramer-APC to detect the percentage of tetramer-positive cells and their
phenotype. The percentage of tetramer+ CD8+ lymphocytes per quadrant is indicated.
Tetramer-positive cells are displayed in black (highlighted), tetramer-negative cells in
grey. Assays were performed ex vivo (C) and after four rounds of stimulation (D).
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Priming of naïve T cells by synthetic artificial APCs results in the generation of
CTLs of the effector memory phenotype
For phenotype analysis, cells were stained with tetramer and appropriate antibodies. In
one stimulation process, 62% tetramer-positive T cells were detected after four rounds
of stimulation (Fig. 2.2 B). Of these tetramer-positive cells, 88% were effector mem-
ory (CCR7− CD45RA−), 9% central memory (CCR7+ CD45RA−), 2% effector (CCR7−
CD45RA+) and 1% naïve T cells (CCR7+ CD45RA+) (Fig. 2.2 D). These results were
confirmed after stimulation and after phenotyping T cells of a second donor, where 80%
of effector memory, 10% central memory, 9% effector and about 1% naïve T cells were
obtained. To compare the phenotype of these tetramer+ specific cells with tetramer+
cells prior to stimulation we also analyzed PBMCs of the same donors ex vivo. One
exemplary result is shown in Fig. 2.2 C. About 70% of tetramer+ cells analyzed ex vivo
were of a naïve phenotype (CCR7+ CD45RA+), as expected from previous reports [30].
The generated CTLs are functional and exert effector functions in a specific fashion
For functional analysis, tetramer-positive T cells generated by the optimal antibody ratio
were sorted and three cell lines were established. Functionality of the T cells was demon-
strated by intracellular IFN-γ staining and chromium release assay. After stimulation
with the Melan-A-expressing HLA-A∗02+ melanoma cell line MeWo, all T cell lines pro-
duced IFN-γ (one representative experiment is shown in Fig. 2.3 A), IFN-γ production
was also observed after stimulation of the T cell lines with either ELAGIGILTV-loaded
T2 cells (Fig. 2.3 B) or the Melan A expressing HLA-A∗02+ melanoma cell line Mel-CG1
(Fig. 2.3 C). (On average, 30-50% of tetramer-specific CTLs produce IFN-γ (Fig. 2.3 A-
C), while irrelevant targets (target cell line loaded with HIV-peptide) did not stimulate
IFN-γ production (Fig.2.3 D, T2 cells loaded with HIV-peptide). These results corre-
spond well with data of generated virus specific CTLs (Rudolf D et al., submitted) and
emphasize our notion that tetramer staining indicates specificity but not functionality of
T cells. Furthermore, the same T cell line lysed the Melan-A-positive targets specifically
and efficiently (MeWo, Mel-CG-1 and ELAGIGILTV-loaded T2 cells, but there was no
lysis of control targets (BV-173 cells and T2 cells loaded with an HIV-peptide) (Fig. 2.3
E). To exclude unspecific lysis of the melanoma cell lines, we tested T cell lines gen-
erated from the sorted tetramer-negative cells. Neither ELAGIGILTV-loaded T2 cells
nor MeWo cells were lysed by the control cell lines (data not shown). This indicates
that the tetramer-positive CTLs killed the melanoma cells in an antigen-specific fashion.
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Figure 2.3: Tetramer-positive cells are fully functional cytotoxic T lympho-
cytes.
Intracellular IFN-γ staining of sorted tetramer-positive T cells stimulated with (A)
HLA-A*02-positive Melan-A-positive MeWo cells. (B) ELAGIGILTV-loaded T2 cells,
(C) HLA-A∗02-positive Melan-A-positive Mel-CG1 cells. The percentage of IFN-γ
producing CD8-positive T cells among tetramer-positive cells is indicated. (D) Tar-
get cells (T2 cells) loaded with irrelevant HIV-peptide do not induce secretion of
IFN-γ (Tetramer-positive cells are displayed in black (highlighted), tetramer-negative
cells in grey). (E) The killing activity of the same T cell lines was tested against
ELAGIGILTV-loaded TAP-deficient T2 cells (filled square), the HLA-A∗02-positive
Melan-A-positive melanoma cell lines MeWo (filled diamond) and Mel-CG-1 (filled tri-
angle). ILKEPVHGV-loaded T2-cells (HIV-peptide, open square) and the HLA-A∗02-
positive leukemia cell line BV-173 (open triangle) were used as control. One of three
independent experiments with comparable results is shown
CD8, CD28, and 4-1BB surface marker expression during stimulation of CD8+ T
cells with aAPCs
To assess cell division and surface expression of the costimulatory molecules CD28 and
4-1BB during in vitro stimulation, naive CD8+ T cells were labeled with CFSE and
then stimulated with A∗0201/ELAGIGILTV-coated microbeads loaded with anti-CD28
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and anti-4-1BB in a 1:3 ratio. After three stimulations, cells were stained with tetramer
and appropriate antibodies. The CFSE labeling indicates that within the CD8+ T cell
population, tetramer+ T cells proliferated almost exclusively during stimulation. The
activation was accompanied by a slight down regulation of the CD8 surface molecule in
part of the T cells (Fig. 2.4 A). Expression of 4-1BB was low in CD8+ T cells before
stimulation, as analyzed by ex vivo staining. After three rounds of stimulation, 4-1BB
was expressed again at low levels in tetramer-positive cells while tetramer-negative cells
displayed higher 4-1BB expression (Fig. 2.4 B-C): only 10% of tetramer-positive cells
expressed 4-1BB compared to 90% of tetramer-negative cells expressing 4-1BB on their
surface. The expression of the costimulating molecule CD28 was determined after in
vitro stimulation: 44% of CD8+ T cells expressed CD28 after stimulation; and 63% of
this CD28+ population were tetramer+ T cells (Fig. 2.4 D-E). In summary, the data
reveal that when used in a defined ratio, anti-CD28 and anti-4-1BB boost T cell priming
and expansion by synthetic artificial APCs. As only a specific ratio of the antibodies
resulted in optimal stimulation, this study stresses the importance of defined artificial
APCs for in vitro T cell priming and expansion.
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Figure 2.4: Expression of surface markers CD8, 4-1BB and CD28 during stim-
ulation.
CD8 enriched T cells of a healthy HLA-A2-positive donor were labeled with CFSE and
stimulated three times with A∗0201/ELAGIGILTV-coated microbeads and an optimized
ratio of costimulatory antibodies. Cell division was assessed at various time points by
monitoring the CFSE intensity of these cultures, followed by staining with anti-CD8 and
tetramer staining. a only tetramer+ CD8+ lymphocytes proliferate during stimulation
with artificial APCs. Proliferation is accompanied by a slight decrease of surface CD8.
4-1BB expression is generally low prior to stimulation (B). After three stimulations, 4-
1BB surface expression is low in tetramer+ T cells compared to tetramer− T cells (C).
In contrast, CD28 expression appeared high in tetramer+ CD8+ lymphocytes after stim-
ulation (E) but significant expression was also determined ex vivo (D). The percentage
of PBMCs per quadrant is indicated in all panels. Tetramer-positive cells are displayed
in black (highlighted), tetramer-negative cells in grey
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2.1.5 Discussion
The main goal of this study was demonstrate that synthetic artificial APC could be
used as a tool in adoptive cancer immunotherapy if the stimulatory capacity of this
APC platform is improved. A parallel comparison recently demonstrated that synthetic
bead-based aAPC are superior to dendritic cells [10]. Here, we introduce an additional
costimulating compound and also consider the ratio of costimulatory triggers and its
eVect on the outcome of stimulation, which is an issue that has been neglected until
now. Biotinylated MHC-peptide complexes and biotinylated antibodies were coupled
onto streptavidin-coated microbeads. We used a well-described CTL epitope for the
study, namely the modiWed Melan-A-derived peptide ELAGIGILTV [26] that has al-
ready been used as a target in melanoma immunotherapy. T cell stimulation resulted in
greatly increased populations of antigen-specific CTLs upon stimulation with anti-CD28
and anti-4-1BB. The peak of 48% positive CTLs (1,47,000 cells in absolute numbers) af-
ter three rounds of stimulation was reached upon stimulation with artificial APCs coated
with anti-4-1BB and anti-CD28 in a 3:1 ratio. Thus, approximately 10 ml of peripheral
blood gave rise to nearly 1,50,000 antigen-specific CTLs. The large majority of the gener-
ated CTLs displayed an effector memory phenotype which had been observed previously
in other in vitro priming experiments [10, 12]. They can be distinguished from central
memory T cells by their lack of the CCR7 chemokine receptor. Effector memory T cells
were shown to migrate to peripheral tissues and to exert an immediate effector function,
thereby providing protective memory [31–33]. The effector function of the generated
CTLs was assessed by two functional assays: The CTLs were shown to be capable of
antigen-specific IFN-γ production and target cell lysis. Unspecific lysis of cells, which
would contradict usage in adoptive immunotherapy, was not detectable. On average, 30-
50% of tetramer+ T cells obtained after three rounds of stimulation were able to secrete
IFN-γ. Other groups achieved higher amounts of IFN-γ secreting cells, specific for the
same modified Melan A peptide ELAGIGILTV, only after enrichment using an IFN-γ
antibody [11] or after cloning. Bulk cultures or T cell lines usually encompass differ-
ent subsets with different effector functions [34], including even dysfunctional cells [35].
The risk of inducing dysfunctional T cells during strong and rapid expansion has been
mentioned before [36]. CD28 is critical for initial T cell expansion, whereas 4-1BB/4-
1BBL signalling impacts T cell numbers much later in the response and is required for
the survival and/or responsiveness of the memory CD8 T cell pool. Upon engagement
59
Results and Discussion, Part 1: Artificial antigen presenting cells
with 4-1BB ligand, 4-1BB can offer a CD28-independent costimulatory signal leading to
CD4/CD8 T cell expansion, cytokine production, development of CTL effector function,
and prevention of activated induced cell death [16]. 4-1BB is hardly detectable on the
surface of freshly isolated human peripheral blood T cells but the expression of 4-1BB
is inducible on human T cells. The 4-1BB molecule has been shown to be transiently
expressed after TCR engagement in a precise and narrow window of time [14, 15]. in
vitro the expression peaks at ≈48 h post-activation, is down-regulated and subsequently
remains at a low, almost constant level [13]. We have been unable to detect significant
4-1BB expression on the tetramer-positive T cells due to the low level and transient
nature of its expression. Members of the TNFR family, including 4-1BB are known to
influence cell survival by activating the NF-κB pathway [37, 38], which in turn can lead
to upregulation of Bcl-xL as well as cellular inhibitors of apoptosis 1 and 2. CD28 as
well as members of the TNFR family influence Bcl-xL expression [19, 39–41]. A variable
percentage of unstimulated thymocytes are CD28+ but this is found in high density only
on the CD3+ (bright) CD4/CD8 single positive population. In our experiments, 63%
of activated tetramer-specific CD8+ T cells expressed CD28 after three weeks of stim-
ulation. CD28 expression increases upon cell activation after 12-24 h and persists for
at least 6 days [42]. CD28 appears to be responsible for a first spate of survival signals
and this can then be sustained by inducible costimulatory pathways such as 4-1BB. In
the light of these findings, to perform optimal T cell priming we used artificial APCs
coated with anti-4-1BB and anti-CD28 in a 3:1 ratio. We were able to demonstrate that
this artificial system is highly effective for in vitro priming. Adoptive immunotherapy
of cancer relies on the priming and expansion of rare CTL precursors that are usually
naïve CD8+ T cells. Obviously, these cells would be lost in a setting of unspecific T cell
expansion via anti-CD3 signals where memory T cells have a growth advantage. Hence,
antigen-specific T cell priming and expansion is needed for adoptive immunotherapy of
cancer. Until now, most artificial APC approaches for antigen-specific T cell stimulation
have relied on genetically engineered cell lines. Clearly, this is a suboptimal solution in
clinical immunology where standardised reagents are needed. In this context, synthetic
artificial APCs are preferable for three reasons: First, as no living cells are employed,
synthetic artificial APCs are true "off-the-shelf" reagents; culturing APCs is more cum-
bersome than using synthetic agents. Synthetic artificial APCs can be produced ad
libitum within the shortest time: biotinylated antibodies, MHC-peptide monomers and
microbeads are commercially available and can be stored for long periods of time. They
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can be tailored to suit since all stimulatory parameters can be adjusted. In addition,
synthetic artificial APCs are convenient. Prior to in vitro stimulation, sufficient APCs
for all three rounds of stimulation are prepared and stored at 4◦C. Each week, an aliquot
is transferred to the stimulation experiment and sufficient numbers of APCs from one
batch are therefore available for the entire stimulation procedure. Second, the culture of
cell-based artificial APC lines requires repeated screenings to ensure the quality of the
lines. This is an obstacle in establishing immunotherapy as a routine procedure. An APC
system that requires no maintenance operations will support the use of immunotherapy
for a greater number of patients. For patients with progressive disease in particular it is
vital to provide an APC system that is both readily available and reliable. Third, cellu-
lar APCs are defined to a lesser extent than synthetic approaches. In our view, this is a
drawback of cell-based APCs, such as dendritic cells or genetically engineered cell lines.
It is not only cumbersome and expensive to generate dendritic cells, it is also difficult to
produce fully-mature dendritic cells reproducibly that are necessary for in vitro priming
especially for different donors. Cell based artificial APCs usually express the molecules
involved in the T cell priming process as transgenes. Hence, the number of stimulatory
molecules at the cell surface is unknown and, more important, it is not possible to tune
the expression of costimulatory molecules in order to provide the optimal ratio for stimu-
lation. Another issue is the avidity of in vitro generated CTLs. It was shown that only a
low concentration of MHC-peptide monomers on artificial APCs resulted in high-avidity
T cells [26]. Conversely, a high concentration of MHC-peptide monomers resulted in
low-avidity T cells. This finding is often not taken into consideration when cell-based
artificial APCs transfected with HLA molecules are used [8, 43]. The amount of "signal
1" that these systems provide is undefined and may vary according to culture conditions.
Interestingly, just the combination of two costimulatory signals resulted in an average of
72% positive CTLs after four stimulations, which to our knowledge is the highest value
observed in an antigen-specific in vitro priming experiment. Hence, synthetic artificial
APCs are not only convenient and versatile but also powerful tools for T cell priming
and expansion. In sum, the introduction of complex yet defined synthetic APCs should
allow the convenient generation of large numbers of high-avidity CTLs by an optimized
ratio of MHC:peptide complexes and costimulatory triggers for both therapeutic and
experimental use.
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2.2 CD8+ T cell responses to MUC1.mod (APL)
2.2.1 Introduction
Mucins are high molecular weight glycoproteins that are found almost exclusively on the
apical surface of many glandular epithelia including the gastrointestinal, respiratory, uri-
nary, and reproductive tracts [44–47]. MUC1 is a type I transmembrane glycoprotein,
consisting of a very large (1000-2200 amino acids) extracellular domain comprised of
a series of 20-25 amino-acid tandem repeats(VNTR)(PDTRPAPGSTAPPAHGVTSA)
[48, 49], a 31-amino-acid transmembrane domain, and a short (72 amino acids) cyto-
plasmic tail. MUC1 primarily functions in lubrication and hydration of epithelia and
protection from microbial attack. However, the large extended extracellular domain of
MUC1 also appears to play both adhesive and antiadhesive functions and contributes to
decreased immune response. More recently, MUC1 has been implicated in signal trans-
duction due to interactions of its highly conserved cytoplasmic tail with several signal
transducing molecules [44]. Aside from its normal physiological roles, MUC1 also has
been implicated in progression of numerous types of cancer including breast, colon, lung,
gastric, and pancreatic cancers [44, 47, 50]. MUC1 expression in tumors is greatly in-
creased and accompanied by altered glycosylation and aberrant expression patterns that
become more diffuse when compared to the normal apically restricted pattern.This over-
expression was shown to correlate with aggressiveness of malignancy and poor prognosis
[51, 52], makes MUC1 an attractive and broadly applicable target for immunothera-
peutic strategies [53–59]. Moreover, MUC1 is proposed to help tumor cells evade host
defenses by attenuating immune responses and to promote metastasis through a loss
of cell-cell and cell-extracellular matrix (ECM) contact [47]. Peripheral CD8+ T cells
recognize peptide antigens that are presented in the groove of MHC class I molecules on
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APCs [60]. Recently,the definition of MHC class I allele-specific motifs allowed the def-
inition of epitopes contained within a given antigen and provided new opportunities for
the development of vaccine therapies [60–62]. However, to date, with a few exceptions
(melanoma-associated antigens), there is only limited information about the identity of
CTL epitopes presented by human malignant cells [63]. in vitro immunization methods
using epitopes derived from selfantigens have often proved unsatisfactory because of the
low affinity of the elicited CTLs and, consequently, the lack of a sufficient recognition
of naturally processed antigens by these CTLs [64, 65]. Presentation of antigens by
professional APCs may be critical for the effectiveness of an induced immune response,
and the nature of the APCs can determine the outcome, ranging from immunity to
tolerance [66]. For this thesis we used the The HLA-A∗0201 restricted epitope STAP-
PVHNV (MUC1950−958), which wasidentified by Brossart et al.; [67]. In an attempt to
overcome the relatively poor binding of the natural MUC1 peptide to HLA-A∗0201, we
synthesized single amino acid modificated peptide analogues; through the modification
of amino acid residues involved in MHC binding, we changed the natural HLA-A∗0201
restricted epitope sequence STAPPVHNV into SLAPPVHNV and performed in vitro
priming experiments with the use of artificial antigen presenting cells.
2.2.2 Material and Methods
HLA-B*0201 positive buffy coats were obtained from healthy blood bank donors. PBMCs
were isolated using standard gradient separation (Lymphocyte Separation Medium,
PAA Laboratories, Pasching, Austria). Peptide, refolding, fluorescent tetramers and
MHC coated microspheres Peptides for MHC refoldings were synthesized using stan-
dard Fmoc chemistry. Peptides were STAPPVHNV (MUC1950−958) and SLAPPVHNV
(MUC1.mod950−958). Biotinylated recombinant HLA-B∗0201 molecules were produced
as previously described [48; 49]. Monomers were fluorescence labeled by coincubat-
ing biotinylated HLA monomers with streptavidin-PE or streptavidin-APC (Molecular
Probes, Leiden, The Netherlands) at a 4:1 molar ratio.
Microspheres were 5.60 µm diameter streptavidin coated polystyrene particles with a
binding capacity of 0.064 µg biotin-FITC/mg microspheres (Bangs Laboratories, Fish-
ers, Illinois, USA). Microspheres were washed and resuspended at 2 x 106/well in PBE
(PBS (BioWhittaker/Cambrex Bio Science, Verviers, Belgium) supplemented with 0.5%
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protease-free BSA and 2 mM sodium EDTA (both Sigma-Aldrich,Taufkirchen, Ger-
many)] containing biotinylated MHC in two different densities (high density (HD): 20
nM; low density (LD): 200 pM) and costimulatory antibodies anti human CD28 Ab 9.3
(5 nM) [50] and anti 4-1BBL Ab (15 nM (Becton Dickinson). Suspension was incu-
bated by room temperature for 30 min while agitating. Coated beads were washed three
times, resuspended in PBE and stored for up to 4 weeks at 4◦C. Antigen-specific in vitro
stimulation of human CD8+ T cells CD8 T cells were magnetically enriched by negative
depletion of PBMCs using biotinylated anti-CD8 Ab (5 µg/ml) and streptavidin-coated
MACS beads (Miltenyi Biotec, Bergisch Gladbach, Germany). in vitro stimulations were
performed in 96-well plates with 1 x 106 sorted CD8+ cells plus 2 x 105 coated beads
per well in 200 µl T cell medium consisting of RPMI 1640 containing HEPES and L-
glutamine (Gibco, Paisley, UK) supplemented with 10% heat-inactivated human serum
(PAA, Colbe, Germany), 50 U/ml penicillin, 50 µg/ml streptomycin and 20 µg/ml
gentamicin (all BioWhittaker, Verviers, Belgium). 5 ng/ml human IL-12 p70 (R&D
Systems, Wiesbaden, Germany) was added with beads. Per donor, 30 wells with high
density loaded microspheres and 30 well with low density loaded beads were performed.
After 3-4 days coincubation at 37◦C, fresh medium and 80 U/ml human IL-2 (Chiron,
Ratingen, Germany) was added and cells were further incubated at 37◦C for 3-4 days.
Stimulation was repeated twice before analysing cells by flow cytometry (FACSCalibur,
Becton Dickinson, Heidelberg, Germany).
Tetrameric analysis
Cells were washed in PBEA (PBS containing 0.5% protease-free BSA, 2 mM sodium
EDTA (both Sigma-Aldrich, Taufkirchen, Germany) and 0.01% sodium azide (Merck,
Darmstadt, Germany) and stained with CD8-PerCP clone SK1 antibody (Becton Dick-
inson, Heidelberg, Germany) in the same buffer for 20 min at 4◦C. 100 µg/ml unlabeled
streptavidin (Sigma-Aldrich, Taufkirchen, Germany) was included in same incubation
period. Cells were washed in PFEA (PBS containing 2% FCS (PAN Biotech, Aidenbach,
Germany), 2 mM sodium EDTA (Sigma-Aldrich) and 0.01% sodium azide (Merck)) and
tetramer stained at 4◦C for 30 min in PFEA. Fluorescent MHC tetramers were always
used at concentrations of 5 µg/ml. After washing, stained cells were resuspended in
1% formaldehyde (Merck) in PFEA. Cells were analysed on a four-colour FACSCalibur
cytometer (Becton Dickinson).
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2.2.3 Results and Discussion
For the generation of MUC1.mod950−958 specific cytotoxic T cells, enriched CD8+ T cells
were stimulated for three 7-9 day rounds in the presence of IL-12 with beads coated with
costimulatory antibodies and HLA-A∗0201 monomer. As determined by tetramer anal-
ysis, stimulation with HLA-A∗0201 monomer coated mircrospheres led to generation of
specific cytotoxic T cells with corresponding specificity (Fig. 2.5 D), as CTLs generated
with beads coated with the modified HLA-A∗0201 restricted epitope SLAPPVHNV,
were also specific for the natural epitope STAPPVHNV (Fig. 2.5 C,E). No staining
was observed with an irrelevant tetramer (data not shown). Also no staining was ob-
tained after stimulating the CD8+ T cells with the beads covered with less immunogenic
natural peptide STAPPVHNV (MUC1950−958) (data not shown). No antigen-specific
T cells were detected after ex vivo staining of PBMCs (Fig. 2.5 A,B), consequently
one can say that detected antigen-specific T cells resulted from efficient in vitro prim-
ing. These results suggest that the MUC1.mod peptide analogue SLAPPVHNV may be
more immunogenic than the natural peptides in HLA-A∗0201 donors and should thus be
considered as a candidate for future peptide-based vaccine trials. Moreover, analogues
with greater immunogenicity than their natural counterparts may be useful in shorten-
ing the stimulation time required to obtain the large numbers of peptide-specific effector
CTL populations required for adoptive transfer therapy.
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Figure 2.5: Representative tetrameric analyses of bead stimulated CD8+ T
cells.
CD8+ T cells of 5 HLA-A∗0201 positive donors were stimulated 3 times with artificial
antigen presenting cells, loaded with costimulatory antibodies and with altered pep-
tide ligand HLA-A∗0201 monomer SLAPPHVNV. (A,B) PBMCs of a healthy HLA-A2-
positive donor were stained ex vivo with CD8-PerCP and tetramer to detect the fre-
quency of antigen-specific T cells before stimulation. CD8-enriched T cells of the same
donor were stimulated four times in vitro with A∗0201/SLAPPVHNV-coated microbeads
loaded with anti-CD28 and anti-4-1BB. Positive T cells were detected by tetramer stain-
ing. (C-E) Cells were stained with CD8-PerCP, SLAPPVHNV (MUC1.mod 950−958)
tetramer-APC and natural ligand STAPPVHNV (MUC1950−958) tetramer-PE. Percent-
age of tetramer+ cells within CD8+ T cell population is indicated in each plot.
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3 Results and Discussion, Part 2: Efficient priming of
virus-specific cytotoxic T cells in vitro
3.1 Synthetic artificial APCs: Fast and reproducible in vitro
priming of HCMV-specific T cells from seronegative donors
This manuscript has been composed by Despina Rudolf, Maria-Dorothea Nastke,
Dominik Maurer, Dorothee Wernet, Christian Sinzger, Hans-Georg Rammensee, and
Stefan Stevanovic´. The author of this thesis has performed the experiments leading to
Figures 3.1, 3.2, 3.3, 3.4 and 3.5
Running title: Artificial priming of HCMV CTL from seroneg. donors
Keywords CTLs · Artificial antigen presenting cells (aAPCs) · HCMV· in vitro priming
3.1.1 Abstract
Human Cytomegalovirus (HCMV) is frequently virulent after stem cell transplantion
and remains a significant cause of morbidity and mortality after reactivation. In healthy
HCMV-seropositive individuals HCMV-specific CD8+ T cells typically represent 1-2% of
peripheral CD8+ T cells. Recovery of HCMV-specific cytotoxic T cell (CTL) responses
after stem cell transplantion is correlated with an improved outcome of HCMV disease,
an observation supporting adoptive transfer strategies using HCMV-specific CD8+ T
cells. However, in vitro priming and expansion of CD8+ T cells from peripheral blood of
HCMV-seronegative donors has rarely been successsful. To overcome this limitation, we
used a priming strategy based upon artificial antigen presenting cells (aAPCs). Micro-
spheres coated with defined amounts of MHC molecules and costimulatory antibodies
such as anti-4-1BB and anti-CD28 can serve as highly effective artificial APCs capable to
prime and expand human CD8+ T cells in vitro. Here we demonstrate in vitro priming
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of CD8+ T cells specific for four immunodominant CTL epitopes derived from the pp65
antigen of HCMV and restricted by HLA-A∗0201 or HLA-B*0702. We isolated CD8+ T
cells from HCMV-seronegative donors, stimulated and expanded these for 3 weeks with
aAPCs and succeeded in the generation of high numbers of HCMV-specific CD8+ T cells
able to lyse HCMV-infected targets.
3.1.2 Introduction
Human Cytomegalovirus (HCMV) is responsible for a variety of disease syndromes in
children and adults. While HCMV infection is normally asymptomatic in immuno-
competent individuals [1], this herpesvirus infection still accounts for serious morbidity
and sometimes fatal infections in immunocompromised patients, in particular recipients
of solid-organ or hematopoetic cell allotransplants and individuals with advanced AIDS
[2–4]. Intensified immunosuppression or T cell depletion increasingly performed for unre-
lated and mismatched or haploidentical stem cell transplantation (SCT) further increases
the incidence of and mortality from HCMV infection [5, 6]. Prophylactic strategies are
accompanied by myelosuppression, nephrotoxicity, or both, resulting in an increased risk
for bacterial or fungal infection [7, 8]. In addition, more and more clinical HCMV strains
become resistant to current standard antiviral therapy [9], underlining the need for al-
ternative modalities to prevent and treat HCMV infections. HCMV infection cannot be
eliminated by the immunocompetent host, although the titer of the virus in the mucosa
and peripheral blood is reduced after acute infection and the virus becomes undetectable.
Thus, persistence and latency are established. The individual cell-mediated immune re-
sponses to HCMV largely rely on T cells. High frequencies of HCMV-specific CTLs can
be detected in peripheral blood of healthy HCMV-seropositive donors [10, 11] and there
is a direct correlation between the regeneration of HCMV-specific CTL responses with
an improved outcome of HCMV disease [12]. Based on these findings, the concept of
adoptive immunotherapy has been developed:[13] Adoptive transfer of HCMV-specific
CTL clones [14, 15] or T cell lines [16] has successfully protected patients at risk from
HCMV disease. The first study on adoptive transfer of CD8+ HCMV-specific T cell
clones in allogeneic hematopoetic cell transplant recipients has proven safety and ef-
fectiveness of this approach to restore HCMV-specific cytotoxic T cell immunity [17].
Furthermore, several studies have outlined the significance of antiviral effector functions
of helper T cells in maintaining CTL responses after adoptive transfer [18, 19] and their
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capacity to produce antiviral cytokines [20, 21]. These findings underline the impor-
tance of T cell immunity in the control of HCMV infection and the relevance of T cell
based approaches in therapeutic settings. Nevertheless, a major limitation of adoptive
immunotherapy is the availability of HCMV-specific CTLs as current strategies require
the time consuming generation of antigen-presenting cells (APCs), usually dendritic
cells (DCs), for stimulation protocols. Furthermore, expansion of HCMV-specific CTL
is feasible in HCMV-seropositive donors but is rarely successful in HCMV-seronegative
individuals [22]. Another strategy to expand HCMV-specific CTLs for allogeneic appli-
cations is usage of cord blood that contains many antigen-inexperienced T cells like in
HCMV-seronegative donors [23]. However, the possibility of generating HCMV-specific
T cells from cord blood is limited by its availability. To overcome this limitation, we
demonstrate in this study a highly effective approach for the generation and expan-
sion of HCMV-specific CD8+ T cells: Microspheres coated with defined amounts of
HLA:peptide complexes and costimulatory molecules serve as artificial APCs to stimu-
late blood cells of HCMV-seronegative donors that do not show detectable frequencies
of HCMV-experienced T cells ex vivo. Our strategy was successful in priming and ex-
pansion of CTLs specific for different epitopes of HCMV presented by HLA allotypes
HLA-A∗02 and HLA-B∗07.
3.1.3 Material and Methods
Donors
Leukapheresis products were obtained from healthy blood bank donors of known major
histocompatibility complex (MHC) class I and II types and of known HCMV serostatus.
The local Ethics Committee approved this study. Peripheral blood mononuclear cells
(PBMCs) were isolated from fresh leukapheresis products using standard gradient sep-
aration (Lymphocyte Separation Medium, PAA Laboratories, Pasching, Austria) and
cryopreserved in fetal calf serum (FCS) (PAA Laboratories) with 10% DMSO (Merck,
Darmstadt, Germany) at -80◦C until further use.
Peptide, refolding, fluorescent tetramers and artificial antigen presenting cells
Peptides from HCMV pp65 (Swiss-Prot Accession No. P06725) were synthesized by stan-
dard Fmoc chemistry using a Peptide Synthesizer 433A (Applied Biosystems, Darmstadt,
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Germany) or alternatively using the Economy Peptide Synthesizer EPS 221 (ABIMED,
Langen, Germany). Immunodominant HLA class I restricted peptides were selected
according to published CTL epitope sequences [24]. Peptides were TPRVTGGGAM
(HCMV pp65417−426) [25] RPHERNGFTVL (HCMV pp65265−274) [26], MLNIPSINV
(HCMV pp65120−128) [27] and NLVPMVATV (HCMV pp65495−503) [28]. Synthetic pep-
tides were dissolved at 10 mg/ml in DMSO (Merck), diluted 1:10 in ddH2O and aliquots
stored at -80◦C. Biotinylated recombinant MHC class I molecules and fluorescent MHC
tetramers were produced as described [29]. Briefly, fluorescent tetramers were generated
by coincubating biotinylated HLA monomers with streptavidin-PE or streptavidin-APC
(Molecular Probes, Leiden, the Netherlands) at a 4:1 molar ratio. Microspheres used for
aAPC preparation were streptavidin coated polystyrene particles of 5.60 µm diameter
with a binding capacity of 0.064 µg biotin-FITC/mg microspheres (Bangs Laboratories,
Fishers, Illinois, USA). Microspheres were washed and resuspended at 2 x 106/well in
PBE (PBS (BioWhittaker/Cambrex Bio Science, Verviers, Belgium) supplemented with
0.5% protease-free BSA and 2 mM sodium EDTA (both Sigma-Aldrich, Taufkirchen,
Germany)) containing biotinylated MHC in either high density (HD, 20 nM) or low
density (LD, 200 pM) and two costimulatory antibodies, anti human CD28 Ab 9.3 (5
nM)[30] and anti 4-1BBL Ab (15 nM, Becton Dickinson). Suspension was incubated at
room temperature for 30 min while agitating. Coated beads were washed three times,
resuspended in PBE and stored for up to 4 weeks at 4◦C.
Reagents and media
T cell medium consisted of RPMI 1640 containing HEPES and L-glutamine (Gibco,
Paisley, UK) supplemented with 10% heat-inactivated human serum (PAA, Cölbe, Ger-
many), 50 U/ml penicillin, 50 µg/ml streptomycin and 20µg/ml gentamycin (all BioWhit-
taker). PFEA (PBS/FCS/EDTA/NaN3) was PBS supplemented with 2% heat inacti-
vated FCS (PAN Biotech, Aidenbach, Germany), 2 mM EDTA (Roth) and 0.01% sodium
azide (Merck). TSB (tetramer staining buffer) was PBS (BioWhittaker/Cambrex) con-
taining 50% FCS (PAA), 2 mM EDTA (Sigma Aldrich) and 0.02% NaN3 (Merck).
Antigen-specific in vitro stimulation of human CD8+ T cells
CD8+ T cells were magnetically enriched from PBMCs using biotinylated anti-CD8 Ab
(5 µg/ml) and streptavidin-coated MACS beads (Miltenyi Biotec, Bergisch Gladbach,
Germany). in vitro stimulations were performed in 96-well plates with 1 x 106 CD8
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sorted cells plus 2 x 105 coated beads per well in 200 µl T cell medium. 5 ng/ml human
IL-12 p70 (R&D Systems, Wiesbaden, Germany) was added with beads. Per donor, 20
wells with high density loaded microspheres and 40 wells with low density loaded beads
were used. After 3-4 days of coincubation at 37◦C, fresh medium and 80 U/ml human
IL-2 (Chiron, Ratingen, Germany) was added and cells were further incubated at 37◦C
for 3-4 days. Stimulation was repeated twice before analysing cells on day 21 by flow
cytometry (FACSCalibur, Becton Dickinson, Heidelberg, Germany).
Generation of T cell lines
Sorting was done with a BD FACSAria cell sorter. Sorted tetramer-positive cells were
expanded in the presence of PHA-L, IL-2, and feeder cells (irradiated LG2-EBV and
irradiated allogeneic PBMCs) as described before [31].
Tetrameric analysis
Cells were washed in PBEA (PBS containing 0.5% protease-free BSA, 2 mM sodium
EDTA (both Sigma-Aldrich) and 0.01% sodium azide (Merck) and stained with CD8-
PerCP clone SK1 antibody (Becton Dickinson) in the same buffer for 20 min at 4◦C. 100
µg/ml unlabeled streptavidin (Sigma-Aldrich) was included in same incubation period.
Cells were washed in PFEA and tetramer stained at 4◦C for 30 min in PFEA. Fluo-
rescent MHC tetramers were always used at concentrations of 5 µg/ml. After washing,
stained cells were resuspended in 1%formaldehyde (Merck) in PFEA. Cells were anal-
ysed on a four-colour FACSCalibur cytometer (Becton Dickinson).
Combined tetramer staining/intracellular IFN-γ staining
After 3 rounds of stimulation 106 CD8+ T cells were incubated with autologous PBMCs
pulsed with 5 µ/ml peptide at a ratio of 1:1 for 6 h. Golgi-Stop (Becton Dickinson) was
added for the final 4 h of incubation. Cells were analysed using a Cytofix/Cytoperm
Plus kit (Becton Dickinson) plus Abs IFNγ-FITC (Becton Dickinson), CD8-PerCP
clone SK1 (Becton Dickinson) and fluorescent MHC tetramer-PE. Stimulation with
PMA/Ionomycin was used as a positive control. After staining, cells were analysed
on a four-colour FACSCalibur.
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IFN-γ ELISPOT assay
Multiscreen HA plates (Millipore, Bedford, MA) were coated with 5 µg/ml of mono-
clonal Ab anti-human IFN-γ (1-D1K; Mabtech, Stockholm, Sweden) in PBS overnight
at 4◦C. Unbound Ab was removed by three washings with PBS. After blocking the
plates with RPMI 1640/10% heat-inactivated human serum (1 h, 37 ◦C), PBMCS at
106 cells/well were seeded in triplicates. Antigenic peptides were added at a final con-
centration of 1 µg/ml. Control wells contained PBMCs, PBMCs in the presence of HIV
peptide. Culture medium was RPMI 1640 medium (Bio Whittaker) at a final volume of
200 µl/well. Cells were incubated at 37◦C in 5% CO2 in a water-saturated atmosphere.
After a culture period of 26 h, cells were removed by six washings with PBS/0.05%
Tween 20 (PBS/T). Captured cytokine was detected by incubation for 2 h at 37 ◦C with
biotinylated mAb anti-hIFN-γ (7-B6-1; Mabtech) at 2 µg/ml in PBS/0.5% BSA. After
washing the wells six times with PBS/T, Avidin-Peroxidase Complex (1/100; Vectastain
Elite Kit; Vector, Burlingame, CA) was added for 1 h at room temperature. Unbound
complex was removed by three successive washings with PBS/T and three with PBS
alone. Peroxidase staining was performed with 3-amino-9-ethyl-carbazole (Sigma) for 4
min and stopped by rinsing the plates under running tap water. Spot numbers were
automatically determined with the use of CTL Immunospot S3 Analyzer (S3A). To cal-
culate the number of CD8+ T cells responding to a particular peptide, the mean numbers
of spots induced by HIV peptide alone were subtracted from mean spot numbers induced
by peptide-loaded APC.
HCMV infection of fibroblasts
HLA-B7-positive human foreskin fibroblasts (HFF) were cultured in MEM containing
2.4 mmol/l glutamine, 100 µg/ml gentamicin, and 5% fetal calf serum (MEM5). Fibrob-
lasts were used for experiments between passages 10 and 25. Contamination of cells by
mycoplasma strains was tested by staining of DNA with 4’,6-diamidino-2-phenylindole
dihydrochloride (DAPI, Sigma Aldrich). Cells were discarded if mycoplasma contamina-
tion was detected. HFF were infected at a multiplicity of infection of 5 infectious units
per cell with HCMV strain AD169 for 60 min at 37◦C. Subsequently, virus preparations
were removed, cells were washed with fresh media and maintained at 37◦C until used for
immunological assays. For negative controls, cells were mock-infected in the same way
using medium without virus.
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51Chromium release assay
Standard 5 h 51Cr release assay was performed using either 104 peptide loaded, B*07-
positive HCMV-infected (strain AD169) fibroblasts or HCMV-infected fibroblasts with-
out peptide loading. Unspecific lysis was evaluated by using HLA-matched uninfected
fibroblasts (mock fibroblasts) as control. The 51Chromium release experiment was also
done with peptide loaded JY cells (Epstein-Barr virus-transformed human B lymphoblas-
toid cell line; HLA-A∗0201, B∗0702), or as a control with JY cells without peptide.
Target cells, peptides and 100 µCi Na251CrO4 (NEN Amersham Bioscience, Freiburg,
Germany) were coincubated for 1 hour at 37◦C/5% CO2. After target cells were added
to effector cells in a 96 well plate and incubated for additional 4 hours at 37◦C, 50
µl of supernatant were transferred to a lumaplate (PerkinElmer, Rodgau-Jügesheim,
Germany) and read-out was performed by scintillation counting (1450 Microbeta Plus,
PerkinElmerTM life science). Specific lysis was calculated by 100 x (experimental release
- spontaneous release)/(total release - spontaneous release).
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3.1.4 Results
Priming in vitro by aAPCs induces antigen-specific CD8+ T cells
For the generation of HCMV-specific cytotoxic T cells (CTLs), MACS-enriched CD8+
T cells from HCMV-seronegative donors were stimulated for three weeks in the presence
of IL-12, IL-2, and artificial antigen presenting cells (aAPCs). Each donor was tested
before stimulation for the presence of HCMV-specific CD8+ T cells; none of the donors
appeared positive in such ex vivo assays (Figure 3.1).
Figure 3.1: Ex vivo HLA-tetramer staining of PBMCs of a healthy HLA-A∗02,
-B∗07-positive, HCMV-seronegative donor.
PBMCs were stained with CD8-PerCP and HLA-B*0702/TPRVTGGGAM tetramer-PE
to determine ex vivo frequency of antigen-specific T cells before stimulation. Since class
I tetramers tend to bind unspecifically to B cells, PBMCs were costained with CD19.
No unspecific binding of tetramers to CD19+ cells was observed. HLA-tetramer staining
was also performed using HLA-B∗0702/RPHERNGFTVL, HLA-A∗0201/NLVPMVATV
and HLA-A∗0201/MLNIPSINV tetramer-APC without the detection of any tetramer-
positive CD8+ cells. Data shown are representative of 4 independent experiments per
donor.
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We also confirmed these data by ELISPOT assay (Figure 3.2). A total of 1 x 106 PBMC
were distributed in eight respectively six wells with the adequate peptide and incubated
for 26 hours. As expected none of the tested HCMV-serongetive donors (Figure 3.2
A) was tested positive, in contrast to the tested seropositive donors (Figure 3.2B). As
positive control PHA-L was used, as negative contol PBMCs incubated with HIV peptide
or medium alone.
Figure 3.2: Ex vivo IFN-γ-ELISPOT response of HCMV-pecific T cells from
HLA-B∗0702 restricted peptide TPRVTGGGAM.
The number of T cells secreting IFN-γ in response to the HLA-B∗0702 restricted peptide
TPRVTGGGAM peptide and the HIV peptide in unstimulated PBMC from healthy sub-
jects was examined. The response to the HIV peptide was used as a negative control and
subtracted from the number of T cells secreting IFN-γ in response to the HCMV peptide.
Results from one HCMV-seronegative donor (A) and one HCMV-seropositive donor (B)
are shown. IFN-γ secreting T cells are indicated in each well. No IFN-γ producing cells
could be obtained within the PBMC fraction from the HCMV-seronegtive blood donor
(A), whereas T cells within the PBMC population from the HCMV-seropositive donor
secreted IFN-γ in a high amount compared to negative controls (B).
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Experiments were performed using aAPCs coated with HLA-B*0702/TPRVTGGGAM
monomer or with B∗0702-restricted RPHERNGFTVL but also with either HLA-A*0201-
restricted NLVPMVATV or HLA-A∗0201/MLNIPSINV monomers. CD8+ T cells of 24
different healthy HCMV-seronegative donors were tested for the presence of specific T
cells after three weeks of stimulation. T cells specific for NLVPMVATV were observed in
4/5 HLA-A∗02+ donors tested (Figure 3.3 A, B). T cells restricted to MLNIPSINV, also
presented on HLA-A∗0201, were detected in 2/5 donors (Figure 3.3 C, D), whereas 3 of 5
donors tested were identical with donors tested for HLA-A*0201/NLVPMVATV specific
T cells. Among 11 HCMV-seronegative donors expressing HLA-B∗0702, 8 showed CD8+
T cells specific for TPRVTGGGAM (Figure 3.3 E, F) and 4/6 donors had detectable
CTL populations specific for RPHERNGFTVL (Figure 3.3 G, H). Our data reflect the
degree of immunodominance of HCMV CD8+ T cell epitopes, since response rates agree
well with results obtained from PBMCs of healthy donors [24].
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Figure 3.3: Tetrameric analyses of bead stimulated CD8+ T cells restricted
to HLA-A∗0201 or HLA-B∗0702, from an HCMV-seronegative donor. Rep-
resentative data for stimulations of 20 wells with high density (HD, 20 nM) monomer
coated beads and 30 wells with low density (LD, 0.2 nM) monomer coated beads
are shown. The following HLA tetramers were used in the different panels: (A,HD;
B,LD) A*0201/NLVPMVATV tetramer-APC and irrelevant A∗0201/MLNIPSINV
tetramer-PE, (C,HD; D,LD) A∗0201/MLNIPSINV tetramer-PE and irrelevant
A∗0201/NLVPMVATV tetramer-APC, (E,HD; F,LD) B∗0702/TPRVTGGGAM
tetramer-PE and irrelevant B∗0702/RPHERNGFTVL tetramer-APC, (G,HD; H,LD)
B∗0702/RPHERNGFTVL tetramer-PE and irrelevant B∗0702/TPRVTGGGAM
tetramer-APC. Additionally, cells were stained with anti-CD8-PerCP in all panels.
Percentage of tetramer+ cells within the CD8+ T cell population is indicated in each
plot. Results of stimulations using HLA-A*0201 restricted epitopes are representative
of 4/5 donors for NLVPMVATV and 3/5 donors for MLNIPSINV. Similarly, results
of stimulations using HLA-B∗0702 restricted epitopes are representative for 8/11
independent experiments for the pp65 epitope TPRVTGGGAM and for 4/6 donors
stimulated with RPHERNGFTVL. 85
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Efficacy of in vitro priming and expansion
In this study we performed experiments using two loading strategies and refer to them as
high density (HD) or low density (LD) stimulations. In each experiment we stimulated
20 wells that contained MACS-enriched CD8+ T cells with HD aAPCs. After three
weeks of stimulation 20-40% of the wells were positive. For LD stimulations we used 40
wells and usually 10-12% of them were positive (Figure 3.4). In comparison, stimulations
of CD8+ T cells from HCMV-seropositive donors with aAPC usually leads to HCMV+
T cells in 100% of stimulated wells (data not shown). Stimulation with aAPCs led to
induction of CD8+ T cells with desired specificities as determined by tetramer staining
(upper panels of Figure 3.3). The generated T cells were highly specific as no staining
with irrelevant tetramers was observed (lower panels of Figure 3.3). in vitro priming
with HD aAPCs yielded populations of 0.6-15% specific CD8+ T cells while after LD
stimulations 0.2-5% of stimulated cells from HCMV-seronegative donors were tetramer-
positive. In comparison, percentages of HCMV-specific T cells varied between 0.6-62.3%
after stimulation of CD8+ T cells from seropositive donors (n = 8); the values were
significantly higher than the percentages obtained with seronegative donors (p=0.005,
Mann Whitney Test (data not shown)). In all stimulations, the number of specific T cells
obtained after 3 weeks of stimulation with aAPC appeared donor dependent. Tetramer
staining intensities, however, did not differ between HD and LD stimulations; thus T
cell receptor avidities were similar in all stimulations.
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Figure 3.4: Statistical assembly over the entire stimulations of CD8-enriched
T cells with 4 different HCMV epitopes.
CD8+ T cells of 24 healthy HCMV-seronegative donors were tested for the pres-
ence of specific T cells after three weeks of stimulation. Stimulation experiments
were performed using aAPCs coated with HLA-A∗0201/NLVPMVATV (NL) or HLA-
A∗0201/MLNIPSINV (ML) monomers but also with either HLA-B∗0702-restricted
TPRVTGGGAM (TP) monomer or with HLA-B∗0702-restricted RPHERNGFTVL
(RP). Mean values of tetramer-positive wells are depicted in vertical bars for each
HCMV-epitope, error bars represent the SEM. Total numbers of stimulations are in-
dicated under each bar.
Functional characterization of in vitro stimulated CD8+ T cells
CD8+ T cells specific for HLA-B∗0702/TPRVTGGGAM were analyzed on day 21 for
their functional capacity to produce IFN-γ. Therefore, tetramer staining in combination
with intracellular IFN-γ-staining was performed after stimulating specific T cells with
peptide-loaded autologous PBMCs. As shown in Figure 3.5, CD8+ T cells recognizing
the epitope TPRVTGGGAM presented by HLA-B∗0702 were capable of producing IFN-
γ. Double staining revealed that on average, 30-50% of tetramer-specific CTLs produce
IFN-γ, which emphasizes our previous notion that tetramer staining indicates specificity
but not functionality of T cells [32, 33]. The vast majority of specific CD8+ T cells after
stimulation was CCR7− and CD45RA− indicating an effector memory phenotype (data
not shown).
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Figure 3.5: Functionality of CD8+ T cells specific for peptide TPRVTGGGAM.
Intracellular IFN-γ-staining combined with B∗0702/TPRVTGGGAM tetramer-PE and
CD8-PerCP surface staining. Tetramer+ CD8+ T cells capable of producing IFN-γ are
highlighted in blue. Non-IFN-γ producing tetramer+ CD8+ T cells are highlighted in
green. These data are representative for one of three independent experiments.
To further characterize the functionality of the generated CD8+ T cells, cells were poly-
clonally expanded and used in a 51Cr release assay to analyse their ability to lyse antigen
presenting target cells. HCMV-specific CTLs did not only efficiently lyse JY cells with
the cognate peptide antigen (Figure 3.6), but also allogeneic fibroblasts, peptide pulsed
or infected with the HCMV strain AD169 presenting the endogenously processed epi-
tope. The antigen specificity of the generated T cells for the HCMV pp65 peptide
TPRVTGGGAM could be further confirmed by the lack of lysis of mock fibroblasts and
JY cells without peptide. HCMV pp65-infected fibroblasts positive for HLA-B∗0702 were
used as antigen presenting target cells either loaded with peptide TPRVTGGGAM or
unloaded, respectively. Specific lysis of both target cell lines could be detected by mea-
surement of 51chromium release in the supernatant of cells after 5 hours of incubation.
TPRVTGGGAM-specific T cells were able to lyse target cells that naturally processed
the pp65 antigen, reflecting a highly effective functionality, while HLA-matched unin-
fected fibroblasts (mock fibroblasts) as controls were not affected (Figure 3.6).
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Figure 3.6: Specific lysis of HCMV-infected cells by TPRVTGGGAM-specific
T cells.
Standard 5 h 51Cr release assay was performed to analyse the lytic activity of in vitro
primed and expanded T cells. HLA-B∗0702 expressing fibroblasts were infected with
HCMV and used as target cells either loaded with peptide TPRVTGGGAM or with-
out peptide, as well as JY cells loaded with peptide TPRVTGGGAM. Unspecific lysis
was evaluated using HLA-matched uninfected fibroblasts (mock fibroblasts) or JY cells
without peptide.
3.1.5 Discussion
It has been demonstrated that T cell immunity is crucial to prevent HCMV reactivation,
which underlines the chances of T cell based approaches in therapeutic settings. Antigen-
specific CD8+ T cell lines in particular have been shown to mediate protective immunity
in patients who are at risk of HCMV disease, e.g. recipients of solid-organ or hematopo-
etic cell allotransplants [23]. Here, we present a highly efficient T cell priming method-
ology to generate functional CD8+ T cells specific for different HCMV epitopes from
HCMV-seronegative healthy donors. Biotinylated MHC:peptide complexes and biotiny-
lated antibodies coupled onto streptavidin-coated microbeads served as artificial antigen
presenting cells. For this study we used well-established immunodominant CTL epi-
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topes [24], HLA-B∗0702/TPRVTGGGAM, HLA-B∗0702/RPHERNGFTVL, and HLA-
A∗0201/NLVPMVATV as stimulatory antigens as well as one subdominant epitope [24],
HLA-A∗0201/MLNIPSINV. A maximum of 16% tetramer-positive CD8+ T cells was
obtained after three rounds of stimulation with artificial APCs coated with anti-4-1BB
and anti-CD28 in a 3:1 ratio, and with different concentrations of HLA:peptide com-
plexes. Previous studies have demonstrated the generation of antigen-specific CD8+ T
cells of different affinities using different amounts of MHC monomers loaded onto the
beads [31]. High-avidity T cells specific for tumor-associated epitopes are preferentially
generated with a low concentration of MHC:peptide complexes, whereas low-avidity T
cells result from stimulations with aAPCs densely coated with monomers [31]. Stimu-
lating with a low MHC:peptide complex density will result only in proliferation of the
high-avidity clones. High density beads, instead will lead to the stimulation of many
low- and few high-avidity clones. The intensity of HLA-tetramer staining has been ac-
cepted as a direct measure of the affinity of TCR for the MHC-peptide-complex [34–36]
and extrapolated to be an indication of the actual sensitivity of the CTL response to
MHC:peptide density [37]. In contrast to Walter et al.[31] we could not observe that
CTLs generated by low-density beads bound higher amounts of HLA-tetramers during
tetramer analysis. This may be due to the fact that viral T cell epitopes represent
"nonself" structures against which high-avidity TCRs should be available, while tumor
antigens are derived from "self" and high-avidity TCRs should have been depleted dur-
ing thymic selection. We could observe that aAPCs coated with the immunodominant
HCMV pp65 peptide TPRVTGGGAM served as highly efficient stimulators for CTL
responses from healthy donors. Although dendritic cells have been described as profes-
sional antigen presenting cells and useful tools for the stimulation of antigen-specific T
cells in vitro, their generation is time consuming and valuable sources of cells are lost.
Recent studies in our laboratory directly compared both, DCs and artificial APCs, for
their efficacy as antigen presenting cells. We have shown that bead-based aAPCs are
superior to dendritic cells in in vitro T cell priming [31, 32]. Artificial antigen presenting
cells were shown to be effective stimulators not only in recall of T cell responses but also
in direct priming of antigen-specific T cells. The large majority of the generated CTLs
displayed an effector memory phenotype, which had been observed previously in other
in vitro priming experiments [31, 38]. They can be distinguished from central memory
T cells by their lack of the CCR7 chemokine receptor. Effector memory T cells have
been shown to migrate to peripheral tissues and to exert an immediate effector function,
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thereby providing protective memory [39–41]. The effector function of CTLs recognizing
the epitope TPRVTGGGAM from HCMV pp65 was analysed by two functional assays:
it could be demonstrated that the primed CTLs were capable of antigen-specific IFN-
γ production and target cell lysis. On average, 30-50% of tetramer+ T cells obtained
after three rounds of stimulation were able to secrete IFN-γ. Furthermore, unspecific
lysis of targets cells, which would interfere with application in adoptive immunotherapy,
was not detectable. Efficient induction and expansion of HCMV-specific CTLs from
seronegative individuals holds much promise for treatment of HCMV reactivation in
recipients of allogenic stem cell transplantants. Nevertheless, there are still limitations
in the use of HCMV epitopes in immunotherapy. The strikingly high representation of
HCMV-reactive memory T cells in HCMV-seropositive subjects contrasts sharply with
the almost nonexistent HCMV reactivity of T cells from HCMV-seronegative subjects.
Data from Sylwester et al.[42], suggest that cross-reactivity is infrequent to nonexistent
for CD4+ T cells and is uncommon for CD8+ T cells among the many hundreds of total
HCMV epitopes. However, this finding does not mean that CD8+ T cell cross-reactivity
is clinically insignificant but is a limiting factor in the design of immunotherapeutic ap-
proaches covering all patients. Therefore, it is of striking importance to develop efficient
and fast methodologies to generate antigen-specific T cells in vitro. Until now, most
artificial APC approaches for antigen-specific T cell stimulation have relied on geneti-
cally engineered cell lines. Clearly, this is a suboptimal solution in clinical immunology
where standardised reagents are needed. A recent study demonstrated that in vitro
generation of virus-specific CTLs from naive human cord blood lymphocytes is feasible
[24]. However, this approach is limited by the availability and the amount of cord blood
lymphocytes. Taken together, artificial APCs provide several advantages compared to
dendritic cells: They are a synthetic resource with commercially available tools that are
easy to store. No further quality controls are necessary in contrast to using cellular
APCs where levels of presented surface antigens, viability as well as vitality of the cells
need to be tested reiteratively. Considering these facts, artificial APCs are an adjustable
handy system that offers the possibility to align involved components and define opti-
mal conditions for in vitro stimulation processes making them essential tools for in vitro
priming and expansion of antigen-specific T cells.
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3.2 Summary
T cells are important effectors in the defense of human pathogens entering the organism.
CD8+ T cells recognize peptides which are presented by MHC class I molecules and lyse
cells which are infected by viruses or intracellular pathogens.
One aim of this thesis was the development of a fast and reproducible method to prime
and expand functional antigen-specific CD8+ effector T cells. We used the modified
HLA-A∗0201 restricted epitope ELAGIGILTV as a model system. Priming experiments
were performed using artificial antigen presenting cells with defined MHC densities. Dif-
ferent settings for coating aAPCs had to be tested until we came up with an optimized
ratio of 3:1 for costimuatory antibodies anti-4-1BB and anti-CD28, which enabled in
vitro priming of high- or low-avidity effector T cells. To further characterize the T cell re-
sponses, we used fluorescently labeled MHC I tetramers as well as intracellular cytokine
staining and 51Cr release assay. Induced CTLs were of an effector memory phenotype
and therefore fully functional. Repeated stimulation of CD8-enriched T cells of different
donors pointed out that on average a fivefold higher percentage of tetramer-specific T
cells could be obtained by costimulation with anti-4-1BB/anti-CD28 in a 3:1 ratio if,
compared to anti-CD28 alone. The optimal ratio between anti-CD28 and anti-4-1BB,
values of up to 72% of antigen-specific T cells were monitored. Similar results could
be obtained for the HLA-A∗0201 restricted epitope SLAPPVHNV referred to tetramer
staining. T cells specific for this altered peptide ligand recognize the cognate peptide
SLAPPVHNV derived from the tumor antigen MUC1.
HCMV infection is a major cause of death and disease in immunocompromised patients,
especially organ transplant recipients, haemodialysis patients, cancer patients, people
receiving immunosuppressive drugs and HIV-patients. Therefore, it is of utmost re-
maining interest to research for innovative approaches to generate antigen-specific T
cells. The developed artificial priming method was highly effective in priming and ex-
panding HCMV-specific CD8+ T cells from freshly isolated CD8+ T cells from HCVM-
inexperienced healthy donors. As expected the induced effector T cells were capable of
lysing target cells efficiently and secreted INF-γ.
The efficiency of such a highly controlled T cell stimulation system holds great promise
for future therapeutic settings.
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3.3 Zusammenfassung
T-Zellen sind wichtige Effektoren bei der Abwehr von Krankheitserregern im men-
schlichen Organismus. CD8+ T-Zellen erkennen Peptide, die von MHC-Klasse I-Mo-
lekülen präsentiert werden und zerstören Zellen, die durch Viren oder intrazelluläre
Erreger infiziert sind. Die vorgelegte Arbeit hatte zum Ziel, eine Methode zu en-
twickeln, mit der es möglich ist schnell und reproduzierbar CD8+ T-Zellen gegen tu-
morassozierte Antigene zu induzieren und diese zu expandieren. Als Modellsystem
wurde das veränderte HLA-A∗0201 restringierte Epitop ELAGIGILTV, das vom Tu-
morantigen MelanA/Mart1 abstammt, genutzt. Priming-Experimente wurden mit Hilfe
von Antigen-präsentierende Zellen mit kontrollierter MHC-Beladung durchgeführt. Es
mussten verschiedene Beladungsstrategien für die künstlichen Antigen-präsentierenden
Zellen ausgetestet werden, bis schließlich das optimale Verhältnis an kostimulatorischen
Antikörpern von 3:1 (anti-4-1BB zu anti-CD28) ermittelt werden konnte. Mit dieser
Kombination war es möglich in vitro gezielt hoch- oder niedrig-avide Effektor-T-Zellen
zu generieren. Um die Funktionalität der T-Zellantworten näher zu beschreiben wur-
den Tetramerfärbungen, intrazelluläre Zytokinfärbungen und 51Chrom-Freisetzungstests
durchgeführt. Die erzeugten T-Zellen wiesen einen Effektor-Phänotyp auf und waren voll
funktionstüchtig. Durch wiederholte Stimulationsversuche mit T-Zellen verschiedener
Spender konnte gezeigt werden, dass 5-fach größere Tetramer-spezifsche T-Zellpopulationen
mit einer 3:1-Kombination der kostimulatorischen Antikörper, im Vergleich zu anti-CD28
alleine, erzielt werden konnten. Außerdem konnten nach Stimulation T-Zellpopulationen
mit bis zu 72% Tetramer-spezifischer T-Zellen damit erhalten werden. Ähnliche Ergeb-
nisse konnten auch mit dem HLA-A∗0201 restringierten Epitop SLAPPVHNV beobachtet
werden, auch wenn hier noch die funktionalen Tests ausstehen. Die Infektion mit dem
Humanen Cytomegalievirus (HCMV) ist eine der Hauptursachen für den Tod bzw.
schwere Krankheitsverläufe, bei immunsupprimierten Patienten. Daher ist es immer
noch von dringender Notwendigkeit, innovative Ansätze zur Generierung von Antigen-
spezifischen T-Zellen in großer Zahl zu entwickeln. Die zuvor beschriebene Priming-
Methode war auch bei der Induktion und Expansion von HCMV-spezifischen CD8+
T-Zellen, die zuvor aus Virus-unerfahrenen gesunden Spender isoliert wurden, sehr ef-
fektiv. Die induzierten Zellen wiesen wie erwartet eine Effektorfunktion auf. Das hohe
Maß an Effizienz und Kontrolle dieses Systems könnte sich bei zukünftigen immunther-
peutischen Anwendungen auszahlen.
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4 Appendix
4.1 Abbrevations
aAPC artificial antigen presenting cell
Ab antibody
APC allophycocyanin
APC antigen presenting cell
β2m β2-microglobulin
BCIP/NBT 5-bromo-4-chloro-3-indolylphosphate toluidine und nitroblue
tetrazolium
BSA bovine serum albumin
CD cluster of differentiation
CFSE carboxyfluorescein diacetate, succinimidyl ester
CLIP class II-associated invariant-chain peptide
CMV cytomegalovirus
Cr chromium
CTL cytotoxic T lymphocyte
DC dendritic cell
ddH2O bidest water
DMSO dimethylsulfoxid
DRiPs Defective Ribosomal Products
EBV epstein barr virus
EDTA ethylendiaminetetraacetic acid
ELISA enzyme linked immunosorbent assay
ELISpot enzyme linked immunospot assay
ER endoplasmatic retikulum
EtOH Ethanol
FACS fluorescence activated cell- sorting
FCS fetal calf serum
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Abbrevations
FITC fluoresce inisothiocyanate
FSC forward scatter
GvHD graft versus host disease
HCMV human cytomegalovirus
HD high density
HEPES 4-(2-Hydroxyethyl)-piperazin-1-ethan-sulfonsäure
HIV human immunodeficiency virus
HLA human leukocyte antigen
HRP horseradish peroxidase
HS human serume
IFN interferon
Ig immungolobulin
IL interleukin
KIR killer cell inhibitory receptor
LCMV lymphocytic choriomeningitis virus
LD low density
MACS magnetically activated cell sorting
MDa megadalton
MHC major histocompatibility complex
MW molecular weight
n number of experiments
NK cells natural killer cells
PAMP pathogen-associated molecular pattern
PBS phosphate buffered saline
PBL peripheral blood lymphocyte
PBMC peripheral blood mononuclear cell
PCR polymerase chain reaction
PE phycoerythrin
PerCP peridinin chlorophyll protein complex
pH potentia Hydrogenii
PHA phytohemagglutinin
PMA 1-(4-methoxyphenyl)propan-2-amine
PMSF phenylmethylsulfonyl fluoride
RPMI Roswell Park Memorial Institute
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Abbrevations
qRT-PCR quantitative real time polymerase chain reaction
RT room temperature
SEM standard error of the mean
SSC side scatter
TAA tumor associated antigen
TAP transporter associated with antigen processing
TBS tris buffered saline
TCR t cell receptor
TNF tumor necrosis factor
TSB tetramer staining buffer
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